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Abstract  
The ability of Shigella flexineri to spread within and between epithelial cells is essential for 
Shigella infection causing bacillary dysentery. This is a particular problem in the developing 
world. The movement of Shigella within the host cell requires the accumulation of actin at 
one pole of the bacterium and the protein VirG is responsible for this function. While the C-
terminal domain (domain) of VirG is integrated into the outer membrane of Shigella, the 
N-Terminal domain (domain) is exposed on the surface of the bacterium. The -domain 
acts as autotransporter of the domain. The exposed domain has multiple binding 
partners including N-WASP, Vinculin and IcsB that are required for infection in man and cell 
to cell spread. To understand the molecular basis of VirG’s activity, it is first necessary to 
produce the protein in quantity; this study investigates the expression of VirG domain in 
E.coli. The optimum construct corresponded to residues 58-506 of VirG expressed in 
Rossetta-gami cells. 
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Chapter 1 
Introduction
1 
 
1.1 A brief introduction to bacterial infection 
 
Some bacteria, such as Lactic acid bacteria and Bifidobacteria, are not harmful but 
beneficial to humans. However, quite a few bacteria are responsible for diseases in higher 
plants, animals and humans. For instance in humans, tuberculosis, pneumonia and foodborne 
illnesses are caused by pathogenic bacteria. Diseases from bacterial infections include 
tetanus, typhoid fever, diphtheria, syphilis and leprosy.  
 Common pathogenic bacteria are Streptococcus, Pseudomonas, Shigella, 
Campylobacter, Salmonella, enteropathogenic Escherichia coli and mycobacteria. All cause 
potentially lethal infections. For example, the mycobacterium, Mycobacterium tuberculosis 
causes tuberculosis. M. bovis bacilli Calmette–Guérin (BCG) vaccine is available for 
vaccination against tuberculosis and continues to be administered to infants at birth in most 
regions where tuberculosis is endemic. However the BCG vaccine can cause fatal 
disseminated infection in immunosuppressed patients, such as HIV-infected newborns. 
Unlike tuberculosis, the vaccine for shigellosis that is caused by Shigella is still under 
development. 
 Bacteria are classified into two main groups of bacteria, Gram-positive and Gram-
negative. Gram-negative bacteria can cause many types of infections. The tool that is used to 
defferencite the bacteria group is Gram–staining. Gram-staining has four basic steps, primery 
staing with crytal violet, fixing the cell wirh iodine as mordant, decolourization with mixture 
of ethanol and aceton and finaly, counterstaining with safranin. Both Gram-positive and –
negative bacteria are stained deep purple colour when the staining substance, crystal violet 
and iodine, penetrate into the cell wall and form crystal violet-iodine complex during the 
staining process. Bacteria reveal its differenciatation after decolourization and counterstining 
treatment. Gram-positive bacteria and Gram-negative bacteria are stained purple and pink 
respectively (Figure 1.1 and Figure 1.2) after completion of stining process. The difference in 
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colour of the stained bacteria is depending on the organization and the structure of the 
bacterial cell wall. Cell wall is located outside of bacterial plasma membrane (cell 
membrane). The Gram-positive bacterial cell wall consist of the thick proteoglycan layer (20-
80 nm), while the Gram-negative bacterial cell wall are made of two layers, outer membrane 
and thin proteoglycan layer (2-3 nm) (Figure 1.2). The cell wall of Gram-positive bacteria 
shrinks due to dethydration of cell wall during the decoloriaion step. Therefore the staining 
substances are trapped in cell and the bacteria are stained purple. Gram-negative bacteria, on 
the other hand, have a thin layer of proteoglycan that is located between plasma membrane 
and outer membranes. The decolorizer (the mixture of ethanol and acetone) during 
declorization step dissolves the lipid layer of outer membrane of the Gram-negative bacteria. 
The removal of lipid layer expose thin peptidoglycan layer and causes the crystal violet-
iodine complex wash away from the cell. As a result, the cell loses the colour. After 
counterstaining with safranin, the Gram-negative bacteria cell remains pink colour. The 
decolorization step is critical. The crystal violet stain can be removed from both gram-
positive and negative cells if the decolorizing agent is left on too long.   
 
 
Figure 1.1  Image of a Gram stain of mixed Gram-positive cocci (Staphylococcus aureus 
ATCC 25923, purple) and Gram-negative bacilli (Escherichia coli ATCC 11775, red). 
The image was recorded using an optical microscope at a magnification of 1000 times.  
The image is taken from http://commons.wikimedia.org/wiki/File:Gram_stain_01.jpg 
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Figure 1.2. The schematic overview of Gram-positive and -negative cell walls and the 
result of the Gram-staining. (Tripathi et al. 2012 and 
http://www.nmpdr.org/FIG/wiki/view.cgi/FIG/GramStain) 
 
 
1.2 Gram negative bacteria  
 
Many antibiotics inhibit Gram-negative bacteria less effectively than Gram-positive 
bacteria. This is because of the low permeability of the outer membrane barrier that prevents 
ingress of the antibiotic.  Gram-negative bacterial also have outer membrane pumps that 
pump out antibiotics and confer drug resistance.  
Unlike Gram-positive bacteria, Gram-negative bacteria have a thin layer of proteoglycan and 
has extra layer of outer membrane for protection. The outer membrane consists of a 
phospholipid membrane, similar to the cell or plasma membrane. The major comportment of 
the bacterial cell wall is Lipopolysaccharide (LPS). LPS is a highly-branched fatty sugar that 
is attached to the outer membrane and acts as endotoxin that induces fever and shock in the 
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human host. Selective permeability of the outer membrane is retained by transporter protein 
called porins. Porins are embedded in the outer membrane of Gram-negative bacteria and 
control the flow of small moleculars across the inner membrane (IM) into the cytoplasm. The 
small number of drug molecules that traverse the outer membrane through transporters 
similar to porins in antibiotic resistant Gram-negative bacteria can be efficiently inactivated 
by the enzyme such as β-lactamases or is transported to extracellular space.  The process of 
translocation of drug out of the bacterial cell is often catalyzed by widely distributed 
multidrug efflux pumps. Transport of much larger molecules, such as extracellular enzymes, 
toxins and bacterial effectors, use dedicated secretory pathways such as the Type Three 
Secretion System. 
 
1.3 Secretion systems in Gram negative bacteria 
 
Protein secretion plays a central role in modulating the interactions of bacteria with their 
environments. Seven types of secretion systems in gram negative bacteria have been 
described so far. There are named Type One Secretion system (T1SS), Type Two Secretion 
system (T2SS), Type Three secretion system (T3SS), Type Four Secretion System (T4SS), 
Type Five secretion system (T5SS), Type Six secretion system (T6SS) and Type Seven 
Secretion system (T7SS). Figure 1.3 shows the schematic overview of the major protein 
secretion systems in Gram-negative bacteria. Only T4SS is found in both Gram-negative and 
positive bacteria, the other five secretion systems that exclude T7SS are present only in 
Gram-negative bacteria. The T7SS is found in Mycobacteria but this system is not yet well-
characterised. All secretion systems are dedicated to the specific secretion of exoproteins. 
Such proteins are transported from the cell's interior across the cell envelope to extracellular 
space or the host cell cytosol and exhibit various activities useful for bacterial adaptation to 
the environment or for bacterial pathogenicity. 
The secretion systems can be subdivided into Sec-independent and Sec-dependent pathways.  
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The Sec dependent secretion systems, T2SS and T5SS, translocate proteins to extracelluar 
space in two steps. First step is the translocation of the precursor protein to periplasm by 
crossing the inner membrane. This process is achieved by the Tat pathway and Sec pathway 
in T2SS and T5SS respectively. Sec or Tat apparatus are targeted by N-terminus signal 
peptide of the expressed precursor protein. The distinctive difference between two pathways 
is that Sec pathway transports unfolded proteins while Tat system delivers folded protein. Sec 
apparatus is comprised of 4 proteins, SecYEG, SecDF, SecA, and YidC are found. Further 
translocation across the outer membrane is accomplished by a dedicated system- T2SS or 
T5SS. T2SS was found in the Legionella pneumophila or Yersinia Entrocolitica and 
composed of about 16 different proteins. The complex of protein is called secreton that 
embedded in the outermembrane of bacteria. Secreton like complex are also found in the 
T3SS.  
Unlike the Sec dependent secretion systems, T1SS, T3SS, T4SS and T6SS export protein to 
extracellular space by bypassing the periplasm. Three secretion systems (T3SS, T4SS and 
T6SS) have needle-like structures that can penetrate the targeted host cell membrane and 
transports bacterial protein for infection (Figure 1.3).  T1SS is depending on the subclass of 
efflux pumps, either a proton motive force or ATP hydrolysis that is utilized as energy 
source.  
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Figure 1.3 The schematic overview of the six major protein secretion systems (Type I ~ 
Type VI) in Gram-negative bacteria and Type VII secretion system in Mycobacteria. 
(Figure taken from Tyler et al. 2009)  
 
 
1.4 Type Three Secretion System (T3SS)  
The Type III secretion System (T3SS) is an essential determinant of the interaction of 
many different Gram-negative bacteria, such as animal pathogens Salmonella, Shigella and 
Vibrio, plant pathogens Pseudomonas, Xanthomonas, and Ralstonia. The T3SS is 
characterised by host contact–mediated induction, ATPase energy requirement for protein 
secretion and translocation or the protein effectors into host cells. Although the structure of 
whole T3SS has been determined by electron microscopy (Blocker et al., 2001), not all of the 
individual proteins have had their structures solved. T3SS seems has sight variations in 
structure. In T3SS of Shigella flexineri, part of T3SS is embedded in the membrane. The 
outer membrane region (OMR) of T3SS is composed of three rings, OMR1–3. OMR1-2 is 
similar to that which is seen in secretins of the type II secretion system. The C-terminal of 
OMR3 is known to be embedded in the outer membrane and its N-terminal domain is 
periplasmic and soluble. The inner membrane region (IMR) is formed of one thick ring with 
24-fold symmetry which create thinner than that of Salmonella tryphimurium. The structure 
of T3SS is similar to the flagellum that is responsible for the bacterial motility (Figure 1.4). 
There is an evolutional relationship between T3SS and the flagellum, although it is not clear 
if the ancestor was a flagellum or a secretion system, perhaps a secretion system is more 
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probable as the flagellum assembles via a mechanism similar to secretion. (Sophie S. Abby 
and Eduardo P. C. Rocha, 2012) 
The T3SS of Shigella flexneri is composed of an external needle, a transmembrane domain 
and a cytoplasmic bulb. Shigella flexneri MxiH assembles to form the helical needle structure 
(Cordes et al., 2003). The study showed that the structure of helical packing of needles has 
similar parameters to those of the flagella rod, hook and filament, but the needle monomer 
protein displays no primary sequence homology with any flagella axial components. MxiH 
mutants showed several alterations in needle structure and function of the TTSS, 
morphologically (defect of needle length) and physically (reduction of interaction with the 
host cells and non-induced continuous secretion of molecules, Kenjale et al., 2005). These 
results suggest the needle may control the activity of the TTSS directly.  
 
Figure 1.4  The schematic image of flagella and type III secretion system (Yip and 
Strynadka 2006). 
 
1.5 Shigella flexneri 
The Gram-negative bacterium Shigella comprises 4 species: S. dysenteriae, S. 
flexneri, S. boydii and S. sonnei. Shigella is probably most well known as the cause of 
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bacillary dysentery or shigellosis as it is otherwise known. Over 20 million people, mostly 
young children in developing countries, are suffering from the disease and one million people 
are killed by the infection every year. Most cases of infection in the developed countries are 
due to S. sonne, whereas S. dysenteriae and S. flexneri are common species in developing 
countries. Transmission of bacteria to humans occurs when people consume water 
contaminated by faeces from infected individuals. Some symptoms of illness are vomiting 
and diarrhea, which may contain mucus and blood, and the conditions may occur within 2-3 
days after exposure. The ingestion of 100-200 S. flexneri can cause the disease. People 
infected by S. flexneri may develop the condition called Reiter's syndrome that shows pain in 
their joints, irritation of the eyes, and painful urination. It can last for months or years, and 
can lead to chronic arthritis that is difficult to treat.  
Shigella and E. coli share many characteristics. The only reason they were originally 
separated into two different genera was that most of the strains of Shigella can cause bacillary 
dysentery while most of the strains of E. coli do not. This difference between Shigella and E. 
coli was revealed by the recent study of S. flexneri that has been the subject of extensive 
molecular pathogenesis and genetics research. A major difference is that Shigella flexneri (S. 
flexneri) has a large plasmid that contains many virulence associated genes that is not present 
in E. coli. S. flexneri serotype 5a virulence plasmid (Venkatesa et al., 2001), genome 
sequence of S. flexneri serotype 2a strain 301 (Jin et al., 2002), and S. flexneri serotype 2a 
strain 2457T (Wei et al., 2003) were completed relatively recently. Comparison of these 
genomes to that of E. coli. showed that Shigella has specific regions containing many genes 
that encode proteins with roles in virulence and the proteins of the type III secretion system to 
deliver these virulence proteins. Analysis of these virulence genes and their protein products 
will reveal the genetic basis for this pathogenic organism's distinctive lifestyle. 
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1.6 Shigella infection  
Shigella enters the human body via the ingestion of contaminated food or water. Once 
Shigella has accessed the large intestine in the human body it is able to establish an infection. 
Once in the large intestine Shigella crosses the epithelial barrier via the microfold cell (M-
cells, Figure 1.5). Shigella is released from M-cells and encounters resident macrophages that 
engulf and degrade foreign bodies. After bacterium-induced phagocytosis Shigella induces 
apoptosis of the macrophages in order to escape phagocytosis. Apoptosis induced by Shigella  
involves activation of enzyme caspase 1 by Shigella effector protein, IpaB (Hilbi, Moss et al. 
1998), which causes maturation of two inflammatory cytokines, interleukin 1β and 
interleukin 18. The mature peptide of cytokines initiate intestinal inflammation characteristic 
of Shigellosis (Fantuzzi and Dinarello 1999).  
After the release of Shigella from macrophages, the bacterum contacts the basolateral 
side of epithelial cell where it secretes effectors, such as VirA, IpaA, IpaB, IpaC and IcsB, by 
mean of the Type Three Secretion System (TTSS). The translocated effector, VirA is 
involved in rearrangement of the host cell cytoskeleton, resulting in membrane ruffling 
(Figure 1.6). This causes the uptake of Shigella into the epithelial cell by phagocytosis. When 
the bacteria invade the cell an autophagosome is formed which usually results in destruction 
of the invading bacteria. Shigella can escape from this digestive process before the formation 
of autophagolysosome. In the cell, the formation of autophagosome is initiated by Atg 
proteins. The interaction of the two proteins, VirG and Atg5, trigger the digestive process of 
invaded object in host cell. Shigella survives this digestive process in the autophagasome as 
IcsB competes with the binding site on VirG with Atg5. A recent study showed that the IcsB 
deletion mutant in Shigella flexneri was trapped by autophagy within the host cell (Ogawa et 
al., 2005, Ogawa, 2006). This result provided evidence that the effector IcsB is involved in 
escape of Shigella from autophagy. The phagocytic vesicle lyses immediately and the 
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bacteria are released into the cytosol where they multiply. Shigella then initiates actin 
polymerisation within the host cell, which leads to inter- and intracellular movement of 
Shigella and results in dissemination of the bacteria into neighbouring cells (Figure 1.5).    
 
 
 
 
 
 
 
 
                                                    
Figure 1.5 Shigella invasion strategies. (Figure taken from Sansonetti et al., 2001)   
 
 
 
 
Figure 1.6  Membrane ruffling on the basolateral side of epithelial cell by effector VirA 
that is inserted into the host by Shigella.(Picture was taken from Copyright©2004 
Pearson Education Inc., publishing as Benjamin Cummings) 
 
11 
 
Most of the genes required for invasion of epithelial cells and intercellular spread are 
located on the 220kb virulence plasmid, although full virulence also requires the expression 
of chromosomally encoded genes. A study confirmed that a 31kb region of the S. flexneri 
virulence plasmid is responsible for invasive characteristic of the bacterium as transformation 
of the 31kb region of the virulence plasmid conferred the invasive phenotype on E. coli K12 
(Maurelli et al., 1985).  
 
1.7 The Shigella flexneri effector VirG  
A locus of virG was first identified on the Shigella flexneri virulence plasmid pWR100 by 
Bernardini (Bernaridini et al., 1989). VirG is expressed at one pole of the bacteria. It is a 
120kDa surface-exposed outer membrane protein composed of 1,102 amino acid residues 
which form three domains, the N-terminal signal sequence (residues 1-52), domain 
(residues 53-758) and the core (residues 759-1102,Figure 1.7). 
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Figure 1.7. a) Domain structure of VirG showing the and domains and the glycine-
rich repeats within the domain. b) The binding sites for IcSb, vinculin and the 
cleavage site are also indicated.  
 
The domain of VirG is exposed on surface of the bacterial membrane. This domain 
is translocated by the -domain which acts as autotransporter. The glycine rich repeats within 
thedomain have multiple binding domains for N-WASP (Suzuki et al., 1998) and vinculin 
(Suzuki et al., 1996). The recruited N-WASP domains promote assembly of F-actin tails via 
recruitment of the ARP2/3 complex. There is another binding site on the domain. Residues 
320-433 were determined as binding the Shigella effector IcsB and autophagy protein Atg5 
by the study of VirG domain derivatives, which have deletion of sequences in domain 
(Ogawa et al., 2005). This region is responsible for escape of Shigella from autophagy as the 
IcsB mutant assay indicated that binding of autophagy protein Atg5 to VirG induced 
autophagy but induction of autophagy was inhibited by competition of IcsB binding to VirG.  
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The domain of VirG has an IcsP protease cleavage site at Arg758-Arg759, and cleavage 
releases a 95 kDa fragment of VirG.  VirG and IcsP activities are regulated by the regulators 
VirF and VirB. This study shows that the mutation of VirB decreases the activity of IcsP and 
increases the proportion of uncleaved VirG on the surface of the bacterium. Therefore actin-
based motility rises.  The overexpression of IcsP results in more VirG being removed. The 
other study suggested that the VirG in the wild type bacterium is located across the entire 
surface of bacterium by moving VirG from the particular pole, where VirG are delivered, to 
the side part of bacteria on the surface of bacteria body. As VirG were inserted at the 
particular pole, the VirG concentration on the surface of bacterium seems higher at the pole 
than the other part of bacteria even if IcsP cleve the VirG anywhere on the surface of bacteria 
(Steinhauer et al., 1999).  IcsP is not required for polar localization of VirG however; it 
contributes to maintaining a tight polar cap of VirG on the bacterial surface. (Wing et al., 
2004) 
The -domain is embedded in the outer membrane and a structure model of the barrel 
channel consists of amphipathic antiparallel transmembrane strands with interspersed 
hairpin turns and loops (Suzuki et al., 1995). The -domain is capable of translocation of 
passenger polypeptides in the same manner as secretion of the 80kDadomain from the 
periplasmic side of the outer membrane to the external side. Therefore the -domain is 
demonstrated to be the autotransporter for the domain of VirG (Suzuki et al., 1995).  
  
1.8 Localisation of VirG is essential for Shigella invasion system  
Localisation of VirG is crucial for motility in infected cells and defects in the polar 
localisation of VirG reduce the efficiency of bacterial movement to adjacent cells.  
The polar localization of VirG does not require signal peptide-mediated location or the -
domain as VirG-GFP fusion protein without signal peptide or the -domain localized to the 
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pole. Absence of amino acid residues 58-103 and 507-729 decreases the polar localization of 
VirG. These results suggest that these two regions are required for the localization of VirG 
(Charles et al., 2001).  
VirG crosses the cytoplasmic membrane using the Sec apparatus (Brandon et al., 2003). 
When VirG is translocated from the cytoplasm to the outer membrane, it is present transiently 
in the periplasm during transportation (Brandon and Goldberg, 2001).  DegP acts as a 
chaperone at low temperature and a protease at high temperature. A reduction in the quantity 
of VirG on the surface of the bacteria was observed in DegP deletion mutant in both Shigella 
and E.coli without affecting the overall amount of VirG produced. These results suggest the 
folding of VirG in the periplasm or the rapid transit of VirG to the outer membrane may be 
facilitated by DegP (Purdy et al., 2002).  
 
1.9 VirG mediated actin polymerisation during infection by S.flexineri 
The actin-based motility of Shigella is dependent on VirG. The loss of VirG causes a 
reduction of actin assembly and reduction of spread of the bacterium to adjacent cells. The 
initiation of actin polymerisation is by binding to the Neural Wiskott-Aldrich syndrome 
protein (N-WASP).   
N-WASP accumulates at the front of the actin tail and is capable of interaction with VirG 
both in vitro and in vivo. N-WASP is homologous to WASP and has several distinct domains. 
These are Enabled /VASP homology domain (EVH1) containing a pleckstrin homology (PH) 
domain and Calmodulin binding domain (IQ), proline rich region, GTPase binding domain 
(GBD) and Verprolin-homology region, a Cofilin-homology sequence and an Acidic terminal 
segment domain (VCA domain). These domains are required for the actin tail assembly. 
Binding of N-WASP, VirG and Arp2/3 complex initiates actin polymerisation. The 
binding assay using N-WASP chimeras containing PH domain or IQ domain or GBD domain 
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suggested these domains were sufficient for interaction with VirG (Suzuki et al., 2002). After 
binding of N-WASP and VirG, Arp2/3 complex bind to N-WASP. The activation of N-
WASP-Arp2/3 complex requires Cdc42 and this interaction leads to nucleation of actin and 
initiates actin polymerisation (Egile et al., 1999). This model of interaction of N-WASP by 
VirG is shown in Figure 1.8. 
Profilin I also binds to VirG through binding to N-WASP. GST pull-down assay showed wild 
type recombinant Profilin I and wild type recombinant N-WASP binds to VirG. However, 
VirG failed to bind wild type Profilin I when N-WASP mutant (Proline-rich region deletion) 
failed to bind Profilin I and caused loss of the actin tail formation. Also wild type Profilin I 
alone was added to see if cell motility was elevated, however, only the addition of two 
molecules, wild type Profilin I and G-actin, can restore the original motility rate of VirG 
expressed E.coli. As actin nucleation was restored by both Arp2/3 complex and wild type or 
mutant N-WASP, this result suggests that profilin is associated with the elongation of actin 
filaments (Mimuro et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1.8  Simple model of the interaction of VirG and N-WASP.  N-WASP comprises 
VCA and WH1 domains and it is the WH1 domain of N-WASP that interacts with the 
alpha domain of VirG enabling the VCA domain to bind the Arp2/3 complex leading to 
actin polymerisation.  The model shows how the binding of WH1 to the alpha domain 
might reveal the binding surface of the VCA domain via a conformational change in the 
N-WASP protein. 
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N-WASP also has a WIP (WASP Interaction Protein) binding domain. WIP is a proline-rich 
protein of 503 amino acids that has homology in its amino-terminal end to the yeast polarity–
development protein verprolin and contains two regions, actin-and profiling-binding motifs 
(Ramesh et al., 1997). Interaction of N-WASP EVH1 (residues 26-147) and WIP (residues 
461-485) was confirmed by NMR study (Volkman et al., 2002).    
 
1.10 Aims and Objectives 
The aim of this study was to discover more about Shigella flexneri VirG by overproducing 
the protein and studying its properties. The objective was to overproduce the soluble 
(external) α-domain or a sub-domain of the α-domain of VirG, in E. coil for further studies.  
These further studies would include crystallization trials, various biophysical measurements, 
and interaction studies using a number of biochemical and biophysical techniques. 
 
  
 
 
 
 
Chapter 2 
Materials and Methods
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2.1 Materials 
2.1.1 Water 
15.0MΩcm purity water (Distilled water = dH2O) by produced by the ELGA Purelab water 
purifier was used to make up all buffers. Autoclaved dH2O was used for the molecular 
biology experiments. 
 
2.1.2 Restriction Enzymes 
Restriction Enzymes Restriction site 
BamHI 5’G/GATCC 3’ 
NcoI 5’C/CATGG 3’ 
NotI  5’GC/GGCCGC3’ 
XhoI 5’ C/TCGCG 3’ 
DpnI 5’-Gm6A/TC-3’ 
 
Table 2.1 List of restriction enzymes and restriction site that were used for cloning. “/” 
represents the cleavage site (New England BioLabs).  
 
 
2.1.3 Polymerase  
Table 2.2 showed the list of the polymerase that were used for amplification of DNA in 
cloning and site directed mutagenesis. 
 
Polymerase 
KOD Hot start DNA polymerase (Novagen) 
Pfu turbo DNA polymerase (Stratagene) 
Hot start Taq (QIAGEN) 
DNA polymerase (New England BioLab) 
Go Taq DNA polymerase (Promega) 
 
Table 2.2 List of polymerases used for cloning and site directed mutagenesis.  
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2.1.4 Primers  
The table shows the primer sequence for different constructs.  Sequences highlighted in red 
represent restriction enzyme binding sites.  
 
Construct Gene 
encoded 
Direction 
of primer  
Primer sequence 
Single DNA cloning  
 
pET32a 
VirG53 
 
 
VirG 
Residues 
 Ala53-Val506 
Forward 5’- CAT CCA TGG CTA CTC TTT CGG GTA CTC C-3’      
                 NcoI 
Reverse 5’- ATG GGA TCC TCA AAC AGT AAG TTC AGC GTT        
                   BamHI  
TTC TTT CAG -3’            
 
 
pET32a 
VirG53 
 
VirG 
Residue  
Ala53-Val506 
Forward 5’-CAT  CCA  TGG  CTA  CTC  CTC  TTT  CGG  GTA   
                   NcoI 
CTC  AAG  AAC TTC ATT TTT CAG AGG-3’ 
Reverse 5’-ATG GGA TCC TCA AAC AGT AAG TTC AGC GTT  
                  BamHI 
TTC TTT CAG  AT T GAA CTC TCC-3’ 
 
pET32a 
VirG103 
 
 
VirG 
Residue 
Arg103-Ala433   
Forward 5’- CC ATG GCT AGA ACT AAG CTA CGG ATT AAC -3’                                        
          NcoI 
Reverse 5’- CTA CTC GAG CTA CGC CCA GTT ATT TAT  
                   XhoI 
AAT AGC -3’                           
 
pET20b 
VirG53 
 
 
VirG 
Residues  
Ala53-Val506 
Forward 5’-CCA TGG CTA CTC CTC TTT CGG G-3’ 
         NcoI 
Reverse 5’- CTA  CTC GAG CTA AAC AGT AAG TTC AGC-3’                    
                  XhoI                        
 
pET20b 
VirG103 
 
VirG  
Residue 
Arg103-Ala433 
Forward 5’- CC ATG GCT AGA ACT AAG CTA CGG ATT AAC -3’                                        
          NcoI 
Reverse 5’- CTA CTC GAG CTA CGC CCA GTT ATT TAT AAT  
                   XhoI 
AGC -3’                           
Mutagenesis 
 
pGEM2T 
VirG53 
C130S 
 
VirG 
Residue  
Ala53-Val506 
Forward 5’-TGA TAA TAA TGA TGG TAA TAG TGG CGG TAA  
                                                         Point mutation 
TGG TGG TG-3’ 
Reverse 5’-CAC CAC CAT TAC CGC CAC TAC TAT TAC CAT  
                                                Point mutation 
CAT TAT TAT CA-3’ 
 
Table 2.3 List of primers used for DNA amplification 
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2.1.5 Vector 
The Table below (Table 2.4) shows the list of vectors that were used in this study. Most of 
the vectors shown below were protein expression vectors, apart from pGEM®-T Easy 
(Promega) which is a cloning vector. 
Vector Antibiotics Tags 
pGEM®-T Easy (Promega) Ampicillin -- 
pGEX2T(GE Healthcare) Ampicillin N-terminus glutathione  
S-transferase (GST) tag 
pET14b (Novagen) Ampicillin N-terminus 6x Histidine tag 
pET20b (Novagen) Ampicillin C-terminus 6x Histidine tag. 
pET32a (Novagen) Ampicillin C and N-terminus 6x 
Histidine tag.  
pACYC184 * Chloramphenicol 
Tetracycline 
No Tag 
* This vector was kindly donated by a previous lab member 
 
Table 2.4 List of Vectors used for cloning and protein expression. 
 
 
2.1.6 Medium 
 
Luria Bertani medium (LB medium) was used for bacterial cell growth. LB liquid media and 
LB-agar medium were made up to 1 liter of distilled water (see Tables 2.5 and 2.6 for details) 
and sterilised by autoclave. All chemical were from Fisher Scientific. 
 
Amount  Chemicals 
5g NaCl 
10g Tryptone 
10g Yeast extract 
 
Table 2.5 Component of LB medium (per 1 liter) 
 
 
 
Amount   Chemicala 
5g NaCl 
10g Tryptone 
10g Yeast extract 
15g Agar 
 
Table 2.6 Components of 1.5% LB-agar medium (per 1 liter) 
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2.1.7 Competent cells 
The competent cells segregate into two groups (Table 2.7), the first for plasmid applications 
and the second group for protein production.  
Application Competent Cell Selection 
DNA 
replication 
DH 5 alpha (Invitrogen) 
Alpha select (Bioline) 
XL1-Blue (Stratagene) 
Ampicillin 
Ampicillin 
Tetracycline 
Protein 
Production 
 
BL21(DE3) (Bioline) 
BL21(DE3)pLysS (Bioline) 
Origami2 (DE3) pLysS 
Rossetta-gami2(DE3)pLysS 
Ampicillin 
Ampicillin 
Chloramphenicol/Tetracycline/Kanamicin 
Chloramphenicol/Tetracycline 
 
Table 2.7 List of competent cells for cloning and protein expression and the antibiotics 
used for their selection.  
 
 
2.1.8 Antibiotics 
 
Antibotics were used for selection of competent cells. Apart from Tetracycline and 
Chloramphenicol, antibiotics were made up with distilled water (15.0MΩcm purity) and filter 
sterilised using aseptic technique. Stocks were kept at -20oC for long term storage. All 
antibiotics were purchased from Fisher Scientific. 
 
Antibiotics Stock concentration 
(mg/ml)  
Working concentration 
(μg/ml) 
Ampicillin 100 100 
Chloramphenicol 34 35 
Kanamycin 30 30 
Tetracycline 12.5 12.5 
. 
Table 2.8 List of antibiotics used for selection of competent cells. 
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2.1.9 Constructs  
A list shows the different constructs that were produced and used in this study (Table 2.9).  
pGEX2TVirG53 construct was provided by Prof. Chihiro Sasakawa and colleagues 
(University of Tokyo, Japan).   
 
Plasmid name 
 
Inserts 
 
Vector 
 
Tag 
Description 
of  
vector 
Location 
of 
expressed 
protein 
pGEMTEasyVirG53 VirG T53-V506 pGEMTEasy non Cloning vector - 
pGEMTEasyVirG103 VirG R103-A433 pGEMTEasy non Cloning vector - 
pET32aVirG53 VirG T53-V506 pET32a His-tagged 
at  
N-terminus 
Protein 
Expression 
vector 
Cytoplasm 
pET32aVirG103 VirG R103-A433 pET32a His-tagged 
at 
 N-terminus 
Protein 
Expression 
vector 
Cytoplasm 
pET20bVirG53 VirG T53-V506 pET20b His-tagged 
at  
C-terminus 
and  
Signal 
peptide at N-
terminus 
Protein 
Expression 
vector 
Periplasm 
pET20bVirG103 VirG R103-A433 pET20b His-tagged 
at 
 C-terminus 
and  
Signal 
peptide at N-
terminus 
Protein 
Expression 
vector 
Periplasm 
pGEX2T VirG53 
(Provided by Prof. 
Chihiro Sasakawa)  
VirG T53-V506 pGEX2T GST tagged 
at 
 N-terminus  
Protein 
Expression 
vector 
Cytoplasm 
pGEX2TVirG53C130S VirG T53-V506 
Cysteine(C) was 
mutated to 
Serine(S) 
pGEX2T GST tagged 
at 
 N-terminus 
Protein 
Expression 
vector 
Cytoplasm 
Table 2.9 List of plasmids that were constructed in this study 
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2.1.10 Columns 
Columns used are listed below in Table 2.10 
Separation 
method 
Columns Material Molecular weights 
separation range 
Affinity  5ml prepacked HiTrap 
chelating column  
Chelating Sepharose™ 
High Performance 
-- 
Empty  column Glutathione Sepharose -- 
Size exclusion  Superdex 200 10/300 GL Spherical composite of 
cross-linked agarose 
and dextran 
between 10,000 and 
600, 000 
 
Table 2.10 List of columns used for protein purification. All columns were purchased 
from GE Healthcare. 
 
 
2.1.10.1 Chelating Sepharose 
Immobilized-metal affinity chromatography (IMAC) is used for separation of proteins by 
using the characteristic of amino acid residues such as histidine and cysteine that form 
complexes with the chelated metals. Chelating Sepharose is made by coupling a metal chelate 
forming ligand to Sepharose (Figure 2.1).  Chelating Sepharose immobilises the metal by 
chelation. Nickel was used in this study. His-tagged proteins were trapped on the chelated 
Nickel in the column. Any proteins which do not have His-tag will tend to pass through the 
column. The binding capacity of 5ml HiTrap Chelating column is 60mg/column. 
 
 
 
 
 
Figure 2.1 Structure of Chelating Sepharose High Performance and the complex of Ni 
ion and ligand.  Image of Chelating Sepharose structure were obtained from GE 
Healthcare and metal-chelating resin structure from QIAGEN.  
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2.1.10.2 Glutathione Sepharose 4 Fast flow 
Glutathione Sepharose is made of the coupling of highly cross linked agarose and glutathione 
that is linked to agarose by 10-carbon linker arm. GST has an affinity toward to glutathione. 
The total binding capacity is approximately 10 mg recombinant GST protein per ml of beads. 
The Glutahione column is not recommended for use with strong denaturing agents, such as 
urea, as they reduce the binding capacity of GST tag due to its denaturation.  
 
 
2.1.10.3 Spherical composite of cross-linked agarose and dextran 
 
Unlike affinity column, size exclusion columns like Superdex 75 10/300 or 200 10/300, 
separate molecules according to the size.  A bead of Superdex is composed of agarose and 
dextran that produce various pores for the separation. The applications of size exclusion 
column are, for example, buffer exchange, a polishing step in purification, determining 
molecular weight or separation of monomer and dimer. Superdex 200 separates the molecules 
between 10,000 and 600,000 Da. Therefore, any molecules more than 600,000 Da will be 
eluted in the void fraction.  
 
 
 
Figure 2.2 The structure of Superdex beads. The circle represents a bead. The dextran 
chains are covalently linked to a highly cross-linked agarose matrix (GE Healthcare). 
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2.1.10.4 Buffer for protein purification column 
 
Buffers were made up with dH2O (ELGA) and adjusted by concentrated HCl to the (Table 
2.11) appropriate pH. Phosphate buffered saline (PBS) tablets were purchased from Fisher 
Scientific. One tablet was dissolved in 200mL dH2O and produce 0.01M phosphate buffer, 
0.0027M KCl, and 0.137M NaCl.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.11 List of buffers used with the column 
 
 
 
 
 
HiTrap chelating column Size exclusion 
 
 
Purified 
sample  
Binding buffer Elution buffer 
His-
tagged 
VirG  
20mM TrisHCl 
pH7.5, 20mM 
Immidazole, 
500mM NaCl. 
20mM TrisHCl 
pH7.5, 500mM 
Immidazole, 500mM 
NaCl. 
20mM TrisHCl pH7.5, 
500mM NaCl. 
His-
tagged 
VirG 
20mM TrisHCl 
pH7.5, 500mM 
NaCl, 20mM 
Immidazole, 
0.1mM  n-
Dodecyl β-D-
maltoside 
20mM TrisHCl 
pH7.5, 500mM NaCl, 
500mM Immidazole. 
0.1mM  n-Dodecyl β-
D-maltoside 
 
20mM TrisHCl pH7.5, 
500mM NaCl, 0.1mM  
n-Dodecyl β-D-
maltoside 
His-
tagged 
VirG 
20mM TrisHCl 
pH8.0, 10mM 
Imidazole, 
500mM NaCl 
20mM TrisHCl 
pH8.0, 500mM 
Imidazole, 500mM 
NaCl 
 
20mM TrisHCl pH8.0, 
500mM NaCl 
Glutathione sepharose column Size exclusion 
Purified 
sample  
Binding buffer Elution buffer 
GST-
tagged 
VirG 
Phosphate 
Buffered Saline 
(PBS) 
Reduced glutathione 
in PBS 
20mM TrisHCl pH8.0, 
500mM NaCl,10% 
glycerol 
GST-
tagged 
VirG 
Phosphate 
Buffered Saline 
(PBS) 
Reduced glutathione 
in PBS 
20mM Tris-HCl pH 8.0, 
500mM NaCl, 10% 
Glycerol, 10mM DTT. 
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2.2 Methods  
2.2.1 Polymerase chain reaction  
The polymerase chain reaction (PCR) was used to amplify the regions of the gene of interest. 
The reaction requires primers that recognise the gene or part of gene of interest on the 
template DNA.  Primers were designed with 5’-and 3’- restriction enzyme sites (Table 2.1) 
which were be used for insertion of the DNA fragment to the cloning or expression vectors. 
DNA amplification was achieved using primers, deoxynucleotide triphosphates (dNTPs), 
template DNA and DNA polymerase (Table 2.2) and the buffer that was provided.  
The chemicals and DNA were added to 0.5ml sterile PCR tubes. The components of PCR 
mixture are shown in Table 2.12. The mixture was located in the PCR thermocycler to 
facilitate the PCR.  The program of PCR cycle is shown in Table 2.13.  Condition of PCR 
reaction mixture and PCR cycle for amplify virG (residues 52-506) for producing pET32a 
construct were shown in Chapter 4. 
 
Components of reaction mixture for PCR 
 Volume Components 
 10μl 10× reaction buffer 
2μl dsDNA template pGEX2TVirG53 
2.5μl oligonucleotide primer Forward 
2.5μl oligonucleotide primer Reverse 
1.6μl 10mM dNTP mix 
2.0μl Pfu DNA polymerase 
79.4μl ddH2O to a final volume of 100μl 
Total 100μl 
                                                                                                  
Table 2.12 The PCR reaction mixture  
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a) 
Segment Cycles 
 
Temperature Time Steps 
1 1 95°C  45seconds Activation 
2 30 95°C  45 seconds Denature  
60.3°C  45 seconds Annealing  
72°C  2 minute Extention 
3 1 72°C  10 minute Final 
extension 
 
b) 
Segment Cycles 
 
Temperature Time Steps 
1 1 95°C  45 second Activation 
2 30 95°C  45 second Denature  
58.4°C  45 second Annealing  
72°C  2 minute 30 sec Extention  
3 1 72°C  10 minute Final 
extension 
 
Table 2.13 PCR cycle a) VirG Arg103-Ala433 and b) VirG Ala53-Val506 
 
The PCR products were analyzed by agarose gel electrophoresis (see Agarose gel 
electrophoresis later in this Chapter). PCR products were purified using a gel extraction kit or 
PCR purification kit (QIAGEN, PEQlab) prior to enzyme digestion.  
 
 
2.2.2 Enzyme digestion of PCR products and vectors 
 
The amplified PCR product was directly cloned into the appropriate vector (Table 2.4). The 
PCR product and vector were treated with appropriate restriction enzymes  
(Table 2.1) to create unique restriction sites at both sides of gene before the ligation. The 
digested PCR products and vector were purified by PCR purification kit and Gel purification 
kit (QIAGEN, PEQlab) respectively prior to the ligation. Ligated circular DNA was 
transfered to appropriate competent cells (Table 2.7) depending on the application, either 
DNA replication or protein production, for transformation of cells. 
The conditions used for double digestion and ligation are shown below. 
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All chemicals and DNA material (Table 2.14) were mixed in the sterile 1.5ml 
microcentrifuge tubes.  The digestion mixture was left to incubate for one hour. 
 
Double Digestion 
Amount Reagent and DNA sample 
10μl vector or PCR protduct of gene 
2 μl 10x buffer 
1 μl* restriction enzyme #1  
1 μl* restriction enzyme #2  
0.2 μl mM BSA 
5.8 μl Sterile ddH2O 
20μl Total volume of reaction mixture 
                                                         * 10 units 
 
Table 2.14 Double digestion mixture 
 
After the completion of enzyme digestion of PCR products and vector, the reaction mixture 
were purified by agarose gel electropshesis. Gel extraction kit (QIAGEN) was used to extract 
DNA fragment from agarose gel. 
 
2.2.3 Ligation of DNA fragments and vector 
Clean digested PCR product and vector were mixed with Takara ligation mixture (TAKARA) 
that contains T4 ligase. Details of the ligation mixture are shown in the table below. The 
mixture was left to incubate at room temperature for 30 minutes then the mixture was 
incubated at 4oC for 2-3 days. 
 
Ligation 
Amount Reagent and DNA sample   
2 μl  digested PCR product 
6 μl  digested vector 
8 μl  Takara ligation mixture 
Total 16μl 
 
Table2.15 Ligation mixture 
. 
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Ligation for using pGEM-T Easy vector 
Volume Components 
5μl  2xRapid ligation buffer for T4DNA 
Ligase  
1 μl  pGEM-T easy vector(50ng) 
2 μl  PCR products   
2 μl  T4 DNA Ligase (U) 
0 μl ddH2O  
Total 10μl 
 
Table2.16 Ligaton mixture for pGEM-T easy 
 
 
 
2.2.4 Site-Directed Mutagenesis  
QuikChange®Site-Directed Mutagenesis Kit (Promega) was used for mutageneisis of the 
virG alpha domain.  All PCR reaction components (Table 2.17) were mixed in a sterile 0.5 ml 
PCR tube. The thermalcycler was programmed using recommended cycling parameter for 
PfuTurbo DNA polymerase (Table 2.18). 
Components of reaction mixture for PCR 
Volume Components 
5 μl  10× reaction buffer 
4 μl  2.5ng/ μl  pGEX2TVirG53 dsDNA 
template 
1 μl (125 ng)  oligonucleotide primer #1 
1 μl (125 ng)  oligonucleotide primer #2 
1 μl  10 mM dNTP mix  
37 μl ddH2O to a final volume of 49 μl 
Then add 1 μl  PfuTurboDNA polymerase (2.5 U/μl) 
Total 50 μl 
 
Table 2.17 PCR reaction mixture 
 
 
Segment Cycles 
 
Temperature Time 
1 1 95°C  30 seconds 
2 16  95°C  30 seconds 
55°C  1 minute 
68°C  7 minute * 
*1minute/kb: The product was 6.1kbp therefore set up for 7 minutes. 
 
Table 2.18 Cycling program for the mutagenesis method 
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Once DNA amplification was completed, the amplification product was cleaved by adding 1 
μl DpnI restriction enzyme.  The mixture of DpnI and DNA product was gently mixed by 
pipetting and centrifuged at 14,000g for 1 mintue in a microcentrifuge (Eppendorf). The 
reaction mixture was then incubated at 37°C for 1 hour to allow complete cleavage of the 
methylated DNA. 1 μl of digested DNA was transfere to the XL1-Blue competent cells for 
transformation. 100 μl of 2% of 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) 
and 100 μl of 10 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) were spread on LB 
agar plate prior to plating the transformants for white and blue colour selection.  X-gal was 
prepared in dimethylformamide (DMF). IPTG was prepared in dH2O and then filter 
sterilized.  
 
2.2.5 Agarose Gel Electrophoresis for the Separation of DNA Fragments 
Agarose gel electrophoresis has proven to be an efficient and effective way of separating 
digested plasmid and PCR products from the low molecular mass fragments. Molecular 
sieving is determined by the size of pores generated by the bundles of agarose in the gel 
matrix. In general, the higher the concentration of agarose the smaller the resulting pore size. 
Therefore low percentage gels are used for the separation of large DNA fragments. Table 
2.19 showed the separation size of DNA fragment according to the concentration of agarose 
gel.  
 
2.2.5.1 Agarose gel 
An agarose gel was made up with running Tris Acetate EDTA (TAE) Buffer (40 mM Tris-
acetate, 1 mM EDTA). The agarose/buffer mixture was melted by microwave. 5μl of liquid 
ethidium bromide stock (10 mg/ml) were added to 100ml melted the agarose/buffer mixture 
to make final concentration of 0.5 μg/ml. The molten agarose was poured into the gel mold to 
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make gel for DNA separation by gel electrophoresis. The agarose was allowed to set at room 
temperature and then the comb was removed. The gels can be stored at 4 °C until use. 
 
Percentage of 
agarose gel 
Agarose TAE Ethidium bromide 
final concentriaton 
Separation 
size 
0.7% 0.8g  100ml 0.5 μg/ml 800bp-10kb 
0.9% 1g 100ml 0.5 μg/ml 500bp-7kb 
1.2% 1.2g 100ml 0.5 μg/ml 400bp-6kb 
1.5% 1.5g 100ml 0.5 μg/ml 200bp-3kb 
 
Table 2.19 Components of agarose gel for different agarose concentrations. 
 
2.2.5.2 Running agarose gel by gel electrophoresis 
DNA samples were prepared with 6x loading dye (New England BioLabs). DNA sample 
mixtures (10-30 μl) were loaded to the each well on the agarose gel. DNA fragments were 
separation by gel electrophoresis apparatus (Biorad) at 100 V for 1 hour. The gel was 
exposed to UV light and an image of a gel was taken with a gel documentation system. DNA 
bands showed up as orange 
fluorescent bands on the gel. The DNA ladder was run alongside of DNA sample to 
determine the sizes of sample bands.  
 
2.2.6 Transformation of competent cells 
100 µl of competent cells (Table 2.7) was transformed with 1 µl of plasmid (Table 2.9) and 
incubated for 30 min on ice followed by heat-shock (see the table 2.20 for the detail of heat-
shock conditions for each competent cell). 800 µl LB liquid media was added to the cell 
suspension which was then incubated for 1 hour at 37°C. Transformed cell were centrifuged 
at 130,000 rpm (Eppendorf) at room temperature for 1 minute and pellets were resuspended 
with 200µl LB liquid media. Resuspended cells were plated on LB-plates containing 
appropriate antibiotics (Table 2.21). Plates were then incubated at 37°C overnight.  
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Competent Cell 
Heat-shock 
temperature 
(°C) 
 
Duration 
(sec) 
DH 5 alpha (Invitrogen) 42 45 
Alpha select (Bioline) 42 45 
XL1-Blue (Stratagene) 42 45 
BL21(DE3) (Bioline) 42 30 
BL21(DE3) plysS (Bioline) 42 30 
Rosetta-gami™2 (DE3) pLysS 42 30 
 
Table 2.20 The condition of heat-shock treatment for transformation of competent cells 
 
2.2.7 Plasmid DNA purification 
After transformation for DNA amplification, each single colony was inoculated into 5ml of 
LB media with appropriate antibiotics (Table 2.21). The cell culture was incubated at 37oC 
for overnight on the shaker. The overnight cell culture was then centrifuged to separate the 
cell culture from medium. The collected pellet was used to purify DNA by using a DNA 
purification kit (QIAGEN, PEQlab). Purification was carried out by following the procedure 
in the kits. Purified DNA was extracted with 50µl of sterilised dH2O and stored at -20
oC.  
Alternatively pelleted cell culture was frozen at -20oC for long term storage. These plasmids 
were used for transformation.  
 
2.2.8 Protein production 
After the transformation of cells for protein production, a single colony was selected 
and inoculated in 10ml of LB liquid medium which had appropriate antibiotics (Table 2.21) 
for overnight at 180rpm at 37oC. 750ml of overnight culture were mixed with 250ml of 
sterilised glycerol to make glycerol stocks that were kept in -80oC. 10ml of overnight culture 
was transferred to 1L of LB liquid media with appropriate antibiotics (Table 2.21). 1L of cell 
culture was grown at 37oC for 3-4 hours until the optical density was approximately ~0.6 at 
600nm. Final concentration of 0.5~1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
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added to the cell culture for induction of recombinant protein production. The cells were spun 
down at 8,000 rpm for 15minutes at 4oC using a Avanti centrifuge (Beckman using a JA10 
rotor) after further 3 hours or overnight of incubation at 18-37oC. The pellet was resuspended 
in 10-30ml of binding buffer (Table 2.24). Pellets were immediately used for the sonication 
step or kept in -20oC for storage for future use.  
 
                                
                      Vector 
Cell 
 
pET32a 
 
pET20b 
 
pET14b 
E.coli BL21 DE3  Amp (100µg/ml)* Amp (100µg/ml)* Amp (100µg/ml)* 
E.coli BL21 DE3 
plysS  
Cam (25µg/ml)* 
 Amp (100µg/ml)* 
Cam (25µg/ml)* 
 Amp (100µg/ml)* 
Cam (25µg/ml)*  
 Amp (100µg/ml)* 
E.coli Rosetta-gami 
2 DE3 plysS 
Cam (25µg/ml)* 
Tet (12.5µg/ml)* 
Amp (100µg/ml)* 
Cam (25µg/ml)* 
 Tet (12.5µg/ml)* 
Amp (100µg/ml)* 
Cam (25µg/ml)* 
 Tet (12.5µg/ml)* 
Amp (100µg/ml)* 
Amp: Ampicillin, Cam: Chloramphenicol, Tet: Tetracycline *(Final concentration) 
 
Table 2.21 Antibiotics used for selection 
 
2.2.9 Protein purification 
Protein purification protocols contained one or more chromatographic steps. The basic 
procedure in chromatography is to pass the solution containing the protein through a column 
packed with various beads. The various proteins interact differently with the column material, 
and can thus be separated by size or affinity of the protein towards the beads. Most proteins 
are detected by their absorbance at 280 nm or the Bio-Rad Protein Assay that is based on the 
method of Bradford when they are coming off the column.  
 
2.2.9.1 Column preparation for affinity column and size exclusion column 
The table shows the conditions used to run columns. (See Table 2.11 for list of the Buffers 
for each column.)  
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Column Condition 
Flow rate  Fraction (ml) 
5ml prepacked HisTrap 
chelating column 
1-5ml per min 5ml  
Superdex 200 10/300GL 0.5-1ml per min 1ml 
Superdex 75 10/300GL 0.5-1ml per min 1ml 
 
Table 2.22 FPLC parameters used for protein purification 
 
2.2.9.2 Sample preparation and purification by HiTrap chelating column 
Hexahistidine (His6) is a popular tag for recombinant protein due to its small size and 
affinity for Ni2+ ions. Unlike other commonly used tags, Glutathione s Sepharose, His6 tag 
can be used under the denaturing conditions.   
HiTrap Chelating column (GE Healthcare) was used for His-Tagged protein 
purification. HiTrap Chelating column was regenerated with 2.5 ml of 0.1 M Nickel sulphate 
salts (NiSO4) in distilled water and then washed with 50ml of dH2O prior to loading 
supernatant.  The regenerated columns were then equilibrated with binding buffer (Table 
2.22).    
The pellets were kept on ice to prevent degradation of the protein by heat. 20ml of 
induced cell culture pellet were sonicated (VibraCell) for 30 sec and rest for 1 minute. The 
sonication interval were repeated for 17 times and then centrifuged by 18,000 rpm for 30 
minutes at 4oC by Avanti centrifuge (Beckman). The supernatant and pellet were applied to 
12% SDS-PAGE gel to determine the extent of expression of recombinant protein.  
20ml of supernatant was loaded on to pre-packed 5ml HisTrap column. Following 
purification was performed on an AKTA system (GE Healthcare). The column was washed 
with 25ml binding buffer (Table 2.11) then eluted against a gradient from 0%-100% of 
elution buffer (Table 2.11). 5ml of sample were collected per faction. Each fractions of 
protein sample were checked by 12% SDSPAGE gel. High concentration of protein sample 
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were pooled and concentrated by MWCO 10,000 vivaspin (Generon) concentrator for further 
purification. 
 
2.2.9.3 Sample preparation and purification by Glutathione Sepharose column  
Glutathione Sepharose column was used for purification of Glutatione S-transferase 
(GST)-tagged protein.  3ml of Glutathione Sepharose 4 fast flow bead (GE Healthcare) were 
packed into a clean plastic column (PD-10, GE Healthcare) and washed with 30ml of PBS.   
The pellets were kept on ice to prevent degradation of the protein by heat. Induced 
cell culture pellet were resuspended with 20ml of PBS and then sonicated by sonicatior 
(VibraCell) for 30 sec and rest for 1 minute. The sonication were repeated for 17 times and 
then centrifuged by 18,000 rpm for 30 minutes at 4oC by Avanti centrifuge (Beckman). The 
supernatant and pellet were applied to 12% SDS-PAGE gel to determine the extent of 
expression of recombinant protein.  
10ml of supernatant were loaded into the column and incubated at 4 oC for one hour. 
After the incubation, applied supernatant were passed through the column. Incubation and 
elution were repeated until all supernatant were loaded to the column. The column was then 
washed with 30ml of PBS in order to wash out contaminants. The protein concentrations of 
flow through fraction were checked by BioRad protein assay solution. Mixture of 10µl (10 
units) of thrombin (1u/µl) and 3ml of PBS were added to the glutathione Sepharose column 
to cleave the GST tag from fusion protein. The column was incubated at 4oC overnight. 
Protein sample were eluted at 4oC. An extra 3ml PBS were added and the sample was eluted 
after one hour of incubation at 4oC. Each fraction of the protein sample was checked by 12% 
SDS-PAGE. Eluted fractions were pooled and concentrated by MWCO 10,000 vivaspin 
(Generon) concentrator for further purification. 
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2.2.9.4 Purification by size exclusion chromatography 
Unlike affinity column, proteins do not bind to the beads in a size exclusion column. The size 
exclusion column separates molecules according to differences in size as they pass through a 
packed gel filtration medium in a column.  Superdex 200 10/300 GL and Superdex 75 10/300 
GL column (GE Healthcare) were used in this study.  Each size exclusion column has 
different fractionation range (see table 2.22).  
Size exclusion columns were washed with 36ml (1.5 column volumes) of buffer (Table 2.11) 
prior to loading the sample.  
Concentrated protein was centrifuged at 13,000rpm (Eppendorf) for 10 minutes at 4oC to 
separate any precipitated material in the solution. Up to 1ml of supernatant was loaded to the 
column.  Protein purification was performed by AKTA (GE Healthcare). Separation was run 
for 1.5 column volumes. Table 2.22 shows the purification running conditions for the AKTA. 
Each fraction of protein was checked by 12% SDS-PAGE. Eluted fractions containing a high 
concentration of protein of interest were pooled and concentrated by MWCO 10,000 vivaspin 
(Generon) concentrator for further experiments. 
 
2.2.9.5 Removal of the tags from recombinant protein with thrombin protease  
The tags were removed by incubating tagged recombinant protein with thrombin protease 
(Novagen) in a solution overnight at 4°C. Cleaved protein was purified by running the sample 
through HisTrap or Glutathione Sepharose column using AKTA. 
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2.2.10 SDS-PAGE Gel Electrophoresis for protein 
2.2.10.1 SDS-PAGE gel 
SDS-PAGE was used to separate the protein by size. The SDS-PAGE was made using the 
various components listed in the Table 2.23. The resolving gel was poured between thin glass 
plates by using BioRad SDS-PAGE gel casting system. A layer of ethanol was added to top 
of dried resolving gel to retain straight surface on the gel. When the gel set, the ethanol was 
discarded and the spacer between the glasses rinsed with dH2O. The stacking gel solution then 
was then added and the desired comb (10-15 wells) was inserted between the spacers at the 
top of the set gel to create the well on the gel.  
 
            
              Gel Type 
Solution  
Components 
 
 
5% stacking gel  
(ml) 
 
 
12% resolving gel  
(ml) 
 
 
15% resolving gel 
(ml) 
dH2O 2.7 1.5 1.1 
1.5M Tris-HCl(pH8.8) - 1.3 1.3 
1.0M Tris-HCl(pH6.8) 0.5 - - 
10% SDS 0.04 0.05 0.05 
10% Ammonium 
persulfate 
0.04 0.05 0.05 
30% acrylamide 0.67 2.0 2.5 
TEMED 0.004 0.002 0.002 
 
Table 2.23 List of solution components and volumes for the stacking gel and resolving 
gel used to produce the SDS-PAGE gel. 
 
 
2.2.10.2 Running SDS-PAGE gel 
 
30μl of protein sample and 30μl of 1x SDS loading dye were mixed in the 1.5ml 
microcentrifuge tube and then boiled at 100oC in the heat block for 10 minutes. The mixtures 
were spun down by microcentrifuge (1 mins, 13,000 rpm, Eppendorf) and 30μl of sample 
were loaded on to the 12% SDS PAGE gel. Protein markers were loaded alongside samples 
to guide the determination of the size of protein bands. 
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The Mini-PROTEAN 3 system (Biorad) was used for running SDS PAGE gels. The prepared 
SDS PAGE gel was placed in the electrophoresis tank and run at 100V-200V for 30-60 
minutes until the dye front reach to the bottom of the gel. The gel was then stained using 
staining dye (see the Table 2.24 for details) for 1 minite by microwave then placed on the 
shaker (scientific) for another 15 minutes at 70 rpm. After staining, the gel was destained 
with destaining solution for 1 minute in a microwave (760 V) and then placed on the shaker 
until the protein bands were visible on the gel. 
 
1x SDS running 
buffer 
1x SDS loading dye Staining dye Destaining 
solution 
30.2g 
188g 
Tris-HCl pH8.3 
Glycine 
100mM 
200mM 
Tris  
DTT 
1g 
30%(v/v) 
Comassie blue 
Methanol 
30% 
40% 
Acetic acid 
Methanol 
10g 
~1L 
SDS 
dH2O 
4%(w/v) 
0.2%(w/v)  
 
20%(v/v) 
SDS 
Bromophenol 
 blue 
Glycerol 
1 0 % ( v / v )
 ~1L 
Acetic acid 
dH2O 
~1L dH2O 
 
Table 2.24 List of solutions used for SDS-PAGE experiments. 
 
2.2.11 Protein Crystallisation 
The hanging drop method was used for protein crystallization. 500 µl reagents were added to 
each well on the 24 well plates. 1µl of protein sample and 1µl of screening reagent were 
mixed on the siliconised glass. Automated liquid handling equipment, Mosquito (TTP), was 
also used to dispense protein samples and screening reagents for setting up drops on the 96 
well plates.  
Screening reagent for protein used for the experiments are Structure Screen 1, Structure 
Screen 2 and Morpheus® (Molecular dimensions).  
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3.1 Over-production and purification of the alpha-domain of VirG with pGEX2T VirG 
Suzuki et al. (1998; 2002) reported that the alpha domain of VirG, amino acid 
residues 53-506, was sufficient to bind N-WASP and cause the polymerisation of actin.  The 
pGEX2T plasmid harbouring the DNA corresponding to the alpha-domain was kindly 
provided by Prof. Chihiro Sasakawa and colleagues (University of Tokyo, Japan).  The DNA 
corresponding to the alpha-domain of VirG was amplified using primers with appropriate 
restriction sites and subsequently ligated into the pET14b expression plasmid; this was the 
work of Dr Syeed Hussain.  The advantage of the pET14b expression plasmid is that it 
encodes a hexa histidine-tag which produces a His-tagged protein that can be readily purified 
using a nickel column. 
The quantity of the alpha domain produced by the two expression systems, pET14b and 
pGEX2T, and importantly the solubility of the alpha domain were investigated. The pET14b 
expression system produced only small quantities of the alpha domain of VirG and that which 
was produced was mostly insoluble (results not shown).  However, the pGEX2T expression 
system produced a greater quantity of the alpha domain of VirG and a greater quantity of the 
protein was in the soluble fraction.  The GST domain fused to the N-terminal end of the alpha 
domain of VirG improved the solubility of the protein compared to that of the His-tagged 
protein but still most of the produced VirG was insoluble.  The soluble VirG produced was 
purified using a glutathione affinity column.  Protein was eluted using reduced glutathione 
and the GST-tag was then cleaved overnight using thrombin.  A size-exclusion column was 
then used to separate the GST-domain and the thrombin from the alpha domain of VirG.  
After removal of the GST-tag the alpha domain remained soluble; Fig. 3.1 shows the protein 
before (1) and after (2) cleavage of the GST tag from the alpha domain as analysed by 12% 
SDS-PAGE. VirG remained soluble after cleavage but the result of subsequent gel 
chromatography revealed that VirG has a molecular mass in excess of 200,000 Daltons. 
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Figure 3.1 Overproduction of the alpha domain of VirG in pGEX2T analyzed using 
12% SDS-PAGE. Lanes: M-markers, 1-before and 2-after cleavage of the GST tag 
using thrombin.  The alpha domain of VirG remained in the soluble fraction, but the 
protein has a high mass as judged by size exclusion chromatography. (Marker: 
SeeBlue® Plus2 Pre-Stained Standard, Life technology) 
 
 
 
3.2 Production of VirG 53 protein with pGEX2TVirG53 in Rosetta-gami™2 (DE3) 
pLysS 
 
3.2.1 Rare codon analysis 
Analysis of amino acid of VirG53-506 revealed there were total of 19 rare codons (Rare 
Codon Calculator (RaCC) by NIH MBI Laboratory for Structural Genomics and Proteomics. 
These rare codon included ATA, AGA, CTA and CCC and also double and triple rare codon 
were indicated within the gene of interest (see also Appendix). To supplement these codons, 
E.coli Rosetta-gami™2 (DE3) pLysS (Novagen) was used as host cell for protein production.  
 
 
 
 
 
 
VirG-GST (77kDa)) 
VirG (51.2kDa)                             
GST (26kDa)                               
 
1 2 M 
98 
62 
49 
28 
17 
40 
 
 
 Rare codon 
VirG -
alpha 
domain 
ATA 
(11)* 
----- AGA 
(1)* 
CTA 
(4)* 
CCC 
(3)* 
----- ----- 
Rosetta-
gami 2 
(DE3) 
pLysS 
AUA 
 
AGG AGA CUA CCC GGA CGG 
*The number of codon in the VirG DNA sequence. 
 
Table 3.1  Number of rare codon identified in VirG53-506 by RaCC and rare codons 
that supplied by rare tRNAs in Rosetta-gamiTM2 (DE3)pLysS .   
 
 
 
3.2.2 Protein production 
Transformation and protein production were followed by the methods described in Chapter 2. 
The cell culture was incubated at 37 oC for 7 hours which was long induction duration than 
BL21 (DE3) cell. Final concentration of 1mM IPTG was used at OD of 0.6 for protein 
production and incubated at 30 oC for overnight.  Protein was successfully produced but result 
showed that pGEX2TVirG53 produced in Rosetta-gami™2 (DE3) pLysS cell was detected in 
the insoluble pellets (Figure 3.2).   
 
Figure 3.2 Overproduction of VirG residues 53-506 pGEX2T by Rosetta-gami™2 (DE3) 
pLysS. Lines M: Marker, SUP: supernatant and PPT: pellet. 
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3.3 Production of VirG 53 C130S mutant protein with pGEX2TVirG53C130S in BL21 
(DE3) pLysS 
 
3.3.1 Mutagenesis of alpha domain of VirG 
The results from the size exclusion column showed that VirG aggregates. This might be due 
to the formation of inappropriate disulphide bonds between VirG molecules. There are three 
cysteine residues on the alpha domain of VirG.  Substitution of cysteine at position at 130 
was attempted by mutagenesis. Cysteine 130 was successfully mutated to serine in alpha 
domain of VirG.  The result was confirmed by DNA sequencing (Eurofins MWG Operon).  
The plasmid that produced the mutated alpha domain of VirG53-506 was named 
pGEX2TVirG53C130S.  
 
3.3.2 Optimisation of IPTG concentration for protein production. 
Previous studies with VirG53-506 protein expressed using pET14b and pGEX2T vectors 
revealed that the protein produced was at least partially insoluble and aggregated in the 
solution. To improve the solubility of protein, Cysteine 130 was mutated to Serine within the 
alpha domain of VirG53-506. In this part, plasmid containing the mutated alpha domain of 
VirG53-506 was used. VirG protein was produced by using pGEX32TVirG53C130S plasmid 
transformed into BL21 (DE3) pLysS competent cells with two different IPTG concentrations, 
0.5mM and 1mM. Produced proteins were tagged with the glutatione S-transferase (GST) at 
the N-terminus of VirG protein (VirGC130S-GST). 
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Figure 3.3 Optimization of IPTG concentration for protein induction. Overproduction 
of 53-506 residues of mutated VirG alpha domain with GST tag. Each cell culture was 
induced protein production by 0.5 mM and 1mM IPTG. Lines BF: protein sample 
before IPTG induction. AF: protein sample after IPTG induction. M: Prestain Protein 
Marker (Invitrogen) P7703S 
 
 
Although, the final concentration of 1mM IPTG produced an apparently better yield of 
VirGC130S-GST (Figure 3.3), the final amount of purified protein produced was not greater. 
Therefore, optimisation of the Optical Density (OD) of the cell for protein induction was 
explored. Cell culture was induced to an OD = 0.8 and 1.0 and protein production was 
determined by SDS PAGE. 1mM IPTG was used for protein induction in this experiment 
(Figure 3.3).  
43 
 
 
Figure 3.4 Overproduction of residues 53-506 of mutated VirG alpha domain with GST 
tag. The cell culture was induced at an optical density of 0.8 and 1.0. Lines BF: protein 
samplebefore IPTG induction. AF: protein sample after IPTG induction. M: Prestain 
Protein Marker (Invitrogen) P7703S 
 
 
This experiment clearly suggests that more protein was produced better when the cells were 
grown to an OD of 1.0. 
These conditions were used for protein production of pGEX2TVirG53C130S in E. coli BL21 
(DE3) pLysS cells. 
 
3.3.3 Protein purification  
A GST column was used for first step of VirG53C130S purification. The GST tag was 
cleaved by thrombin from the VirG protein on the column. 15µl of Glutathione Sepharose 
beads were loaded onto a 12% SDS PAGE gel to check if the cleaved GST tag was bound to 
the beads. VirG was confirmed to be in the eluate.  Figure 3.5 shows that the eluted fraction 
contained VirG53C130S and cleaved tags were indeed trapped on the Glutathione Sepharose 
beads.  VirG also appeared in the pellet fraction which shows that some of the protein was 
insoluble.  
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Figure 3.5 VirG53C130S purification using Glutathione sepharose after thrombin 
digestion. 12% SDS PAGE was used to separate protein sample. Lines SUP: 
supernatant, PPT: pellet, FT: Flowthrough fraction, WASH: Wash fraction, ELU: 
Elution fraction and BEAD: Glutathione Sepharose beads. M: 
NEBPrestainProteinMarker P7703S 
 
 
The PBS buffer of the supernatant was exchanged with buffer comprising 20mM TrisHCl pH 
8.0, with various NaCl concentrations (250mM, 400mM, 500mM) by the dialysis  overnight 
at 4oC. The buffer containing 250mM and 400mM caused precipitation of protein during the 
dialysis. Buffer with 500mM NaCl also produced white precipitate during concentration of 
protein solution after dialysis. Therefore 10% glycerol was added to the buffer to aid 
solubility of the protein for further purification by size exclusion column.  The protein had a 
calculated pI of 4.29 (protein without GST tag), PBS has a pH of 7.3; therefore Tris-HCl pH 
8.0 was used as the buffer.  
The eluted protein sample was however slightly cloudy. The precipitation was apparent after 
thrombin digestion and dialysis. The sample was therefore spun down using a 
microcentrifuge at 13,000 rpm for 5mins at 4oC. Separated supernatant and pellet were 
loaded onto a SDS-PAGE gel to identify if the precipitate contains VirG53C130S. 
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Figure 3.6 Analysis of VirG53C130S by 12% SDS PAGE. Lines 1: Supernatant from 
elution fraction after thrombin digestion. 2: Pellet from elution fraction after thrombin 
digestion, 3: Supernatant from protein sample after dialysis 4: Pellet from elution 
fraction after dialysis M: Marker (NEB Prestain Protein Marker). 
 
The VirG53C130S protein was present in all samples (Fig. 3.6).  This result showed that at 
least some of the protein is insoluble.  The protein in the soluble fraction was thought to be 
soluble at this stage. 
The elution fractions still contained contamination. In order to further purify the sample, the 
protein sample was concentrated to 1ml (20.5mg/ml) using 10,000 MWCO Viva spin 
concentrator (Generon) at 3,000 rpm for 20min. 1ml of concentrated protein sample was 
loaded into a Superdex 200 10/300 GL column (GE Heathcare). Two buffers containing two 
different detergents were used to optimise protein solubility for the further protein 
purification steps. The column was equilibrated with 20mM Tris-HCl pH 8.0, 500mM NaCl, 
10% Glycerol or 20mM Tris-HCl pH 8.0, 500mM NaCl, 10% Glycerol, 10mM DTT.  
Fractions were collected 1ml per tube and the elution volume was 1.5 column volumes. 
Protein sample were centrifuged for 10min at 4oC to separate any precipitate present in the 
solution. Eluted protein was checked by SDS-PAGE. 30µl of sample was loaded into the 
12% SDS PAGE gel.   
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Figure 3.7 Protein purification of VirG35C130S using a Superdex 200 10/300 GL 
column.Lines 1: Protein sample before the purification. 2-4: collected fraction.  
 
 
Some of the contaminating protein was separated by size exclusion column chromatography 
but some contamination remained in the same fraction as VirGC130S. VirG remained soluble 
after purification but the result of subsequent gel chromatography revealed that VirG has a 
molecular mass in excess of 200,000 Daltons revealing that it was aggregated. 
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4.1 Overproduction of the alpha domain of VirG using pET32a vector  
VirG protein was found to be either partially insoluble or aggregates in the solution (Chapter 
3).  VirG aggregates might be due to the formation of inappropriate disulfide bonds within 
alpha domain of VirG that has three cysteine residues. pET32a vector has thioreodoxin 
encoded gene which reduces disulfide bonds to enable their rearrangement and facilitate 
folding of the protein. Therefore, expression of the alpha domain of VirG in pET32a may 
help disulfide exchange and the correct folding of the protein. In this chapter, two different 
length of alpha domain VirG (residues 53-506 and 103-433) were amplified and cloned into 
pET32a vector in order to achieve the protein solubility.  
 
4.1.1 virG Polymerase Chain Reaction (PCR)  amplification  
The alpha domain of VirG was amplified by PCR using the following primers.  
Short Sequences Length Tm* 
Primer 
Forward 
   5'-CATCCATGGCTACTCCTCTTTCGGGTACTC-3' 
                 NcoI 
30 59 oC 
primer 
Reverse 
  5'-ATGGGATCCTCAAACAGTAAGTTCAGCGTTTTC -3' 
                BamHI 
33 57 oC 
Long    
Primer 
Forward 
5-CATCCATGGCTACTCCTCTTTCGGGTACTCAAGAACTTCATT 
               NcoI 
TTTCAGAGG-3’ 
51 65oC 
Primer 
Reverse 
5’-ATGGGATCCTCAAACAGTAAGTTCAGCGTTTTCTTTCAGAT  
             BamHI 
TGAACTCTCC-3’ 
51 64 oC 
*Tm = Melting temperature 
Table 4. 1 Primers used for amplification of the alpha domain of virG encoded gene for 
VirG53 
 
 
In order to optimise the PCR amplification of virG, different polymerases, reaction mixtures 
and templates were used.  
Betaine, Dimethyl sulfoxide (DMSO) and MgCl2 were used to optimize the PCR reaction 
mixture. Betaine and DMSO facilitate strand separation as Betaine equalizes the contribution 
of GC- and AT base to the stability of the DNA duplex and DMSO disrupts base pairing. 
Hence, these agents help to increase the primer binding to the single strand template DNA 
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and help to produce a high yield of PCR products. MgCl2 increases specificity of primer 
binding to template DNA. Therefore, this reduces contamination and increases the purity of 
the PCR products. Annealing temperature of the PCR cycle was also optimized depending on 
the primers used (short and long primers are shown in Table 4.1.). 
Table 4.2 shows how the PCR was optimized. 
(a) 
Polymerases Template Optimising the PCR reaction mixture Primers 
Pfu polymerase pET14b::virG ±Betaine(1.2M),  ±DMSO(10%) 
Annealing template: 
See Table 4.2 (b) 
Short  
pGEX2T::virG N/A Short 
Hot start 
polymerase 
pET14b::virG MgCl2 concentration: 
1.5mM,2.5mM,3.5mM 
Annealing template: 
See Table 4.2 (b) 
Short 
Hot start pfu 
polymerase 
pET14b::virG N/A Short 
Taq polymerase pET14b::virG ±Betaine(1.2M),  ±DMSO(10%) Short 
Go Taq 
polymerase 
pET14b::virG Annealing template: 
See Table 4.2 (b) 
Short/ 
Long 
pGEX2T::virG MgCl2 concentration 
2.0mM,2.5mM,3.0mM and 4.0mM  
Annealing template: 
See Table 4.2 (b) 
Long 
 
(b) 
 
    Polymerase 
 
Cycle     
Pfu 
polymerase 
 
Hot start 
polymerase 
Hot start Pfu 
polymerase 
 
Taq 
polymerase 
 
Go Taq 
polymerase 
Initial 
Denature 
95oC 1 min 95oC 15min 95oC 2 min 95oC 2min 95oC 2 min 
Denature 95oC 1 min 95oC 1 min 95oC 30 sec 95oC 30 sec 95oC 1 min 
Annealing 52oC 30sec 52oC 
or 
55Co 
1 min 52oC 30 sec 55oC 30 sec 52oC 
or 
59oC 
1min 
Extension 72oC 3 min 72oC 1 min 
30sec 
72oC 1min 
30sec 
72oC 2 min 72oC 1min 
30sec 
Number of 
Cycle 
30 30 30 35 35 
Extra 
extension 
72oC 5 min 72oC 10 min 72oC 10  min 72oC 7 min 74oC 5min 
 
 
Table 4.2 Optimisation of PCR reactions mixture for amplification of virG alpha 
domain. (a) Table for optimising PCR reaction mixture. (b) Table of PCR cycles for 
each polymerase used.  
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Figure 4.1 a) virG (residues 53-506) PCR products for construct by using GoTaq 
polymerase and long PCR primers. b) Optimized PCR reaction mixture used in this 
study. 
 
 
Table 4.2 shows the final optimized condition used to amplify the virG alpha domain. PCR 
amplified better using Go Taq polymerase and long primers with annealing temperature at 59 
oC.  Amplified PCR products from the reaction mixture containing 3.0 mM and 4.0 mM of 
MgCl2 showed less contaminant compared with the other two conditions (the reaction 
mixture containing 2.0 mM and 2.5 mM of MgCl2). However, latter conditions gave high 
yield the PCR products. The PCR product was extracted by gel extraction kit (QIAGEN). 
pET32a vector (Novagen) and the virG PCR products were digested by two restriction 
enzymes, BamHI and NcoI.  Therefore the virG alpha domain amplified with optimized 
condition of 2.0mM MgCl2 was cloned into the pET32a vector (Novagen) at the site of 
BamHI and NcoI to generate pET32aVirG53construct. For the pETVirG103 construct, 
different primers were used (see table 2.3 for detail.).  The virG (Residues 103-433) PCR 
products were digested by two restriction enzymes, XhoI and NcoI was used and successfully 
ligated into pET32a vector.   
Finalized components of reaction mixture 
for PCR with 2mM MgCl2  
Volume Components 
 10μl Reaction buffer 
1μl dsDNA template 
pGEX2TVirG53 
5μl Long primer Forward 
5μl Long  primer Reverse 
0.8μl 25mM dNTP mix 
0.25μl GoTaq DNA polymerase 
3.75μl ddH2O to a final volume of 50μl 
3.2 μl MgCl2 
Total 50μl 
   MgCl2 concentration(mM)                                                
  M     4.0    3.0    2.5    2.0   M 
 
Kb.p 
 
 
 
1.5 
1.0 
0.8
0.6 
a) b) 
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Figure 4.2 Agarose gel electrophoresis of PCR products. 
 
 
 
 
Figure 4.3 An image of a gel electrophoresis. The image showed the inserted DNA 
corresponding to the alpha-domain VirG103 and VirG53 into pGEMEasy (a and b) and 
pET32a vector (c and d) by agarose gel electrophoresis.  
(a) (b) 
(c) (d) 
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VirG53-His 
(66.5KDa) 
4.1.2 Production and purification of VirG by pET32aVirG construct 
pET32aVirG53 and pET32aVirG103 were transformed into E. coli BL21 (DE3) competent 
cells. A single colony was inoculated into Luria–Bertani (LB) media containing Amp and 
Cam for growth overnight at 37oC. The proteins produced were His-tag at the N terminus of 
VirG protein. 
 
Figure 4.4 Overexpression of VirG residues 53- and 103- with pET32a in BL21 (DE3).  
Black box on the gel shows band of produced VirG53 protein. Pre: Pre-induction 
sample, Post: Post-induction sample  
 
The result from SDS-PAGE showed that VirG53 was produced at both induction 
temperatures (30oC and 16oC) while VirG103 was not produced. Therefore, further 
purification was carried by using pET32aVirG53 in BL21(DE3). 
 
4.1.3 Protein purification of VirG53 produced by E.coli BL21 (DE3). 
Protein samples were prepared by following the method in Chapter 3. The cells were lysed by 
sonication and centrifuged. The supernatant was loaded on to pre-packed 5ml HisTrap 
column (GE Healthcare). The column was washed with 25ml wash buffer (20mM TrisHCl 
pET32aVirG103 pET32aVirG53 
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pH7.5, 20mM Immidazole, 500mM NaCl.) then eluted against a  gradient from 0%-100% of 
elution buffer (20mM TrisHCl pH7.5, 500mM Immidazole, 500mM NaCl.) by automated 
protein purification equipment AKTA FPLC (GE Healthcare). 5ml of elution fractions were 
collected per tube. Each fraction of protein samples were checked by 12% SDSPAGE gel. 
High concentration of protein sample were pooled and concentrated from 40ml to 2.0ml by 
MWCO 10,000 vivaspin (Generon) concentrator.  
 
Concentrated protein samples were then centrifuge at 13,000 rpm for 10 minutes at 4oC to 
extract any aggregated protein in the solution prior to run the column. Protein samples were 
loaded on to a Superdex 200 10/300 column (GE Healthcare) for further purification. The 
column was equilibrated using buffer (20mM Tris HCl pH7.5, 500mM NaCl) before running 
the column. 1.5ml of protein sample was collected per tube. Protein concentration was 
checked by chromatogram and by SDS-PAGE.  
 
 
 
 
Figure 4.5 Concentrated sample VirG. M:NEB  colour plus protein marker 
 
Eluted VirG53 protein was observed in the void fraction. Therefore VirG has a molecular 
mass in excess of 200,000 Daltons (Da). 
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 To improve solubility of protein in solution, final concentration of 0.1mM n-Dodecyl β-D-
maltoside was added to the buffer for all purification method. However, the solubility of 
VirG protein produced was not enhanced.  
 
4.1.4 Protein induction of VirG53 and VirG103 at high E. coli cell density. 
Although protein was produced in the previous experiment, the amount was not sufficient. In 
this study, the E. coli cells were grown to a high density (high O.D) before protein was 
induced. Two different time duration (3 hours and overnight) of protein induction were also 
tested. E. coli harbouring pET32aVirG53 and pET32aVirG103 plasmids were used in this 
study.  pET32aVirG53 and pET32aVirG103 were transformed into E. coli BL21 (DE3) 
competent cells. Proteins were produced with His-tag at N terminus of VirG protein. 
150μl of overnight culture was added to 15ml of LB-Amp media and the cell culture was 
grown at 37oC for 3hours until the optical density was approximately 1.3. 1M IPTG was then 
added to the culture at final concentration of 1mM for induction of recombinant protein 
production. The cells were grown overnight at 30oC and then were harvested at 7000g for 20 
minutes at 4 oC. The cells were spun down after overnight incubation. The pellet was 
resuspended in sonication buffer, and then the cells were lysed by sonication and centrifuged. 
The supernatant and pellet were applied to 12% SDS-PAGE gel to determine the extent of 
over-expression of VirG. Cell pellet of pre-induction sample and post-induction sample were 
resuspended using 30µl of 20mM Tris-HCl pH7.5, 500mM NaCl, 20mM Immidazole and 
mixed with 30µl of loading dye. SDS-PAGE protein samples were boiled at 100 oC for 10 
minutes. 50µl of each protein sample were loaded into the 12% gel. Gel was run for 30 
minutes, 100V. Figure 4.6 shows the protein production in different time schedule. Protein 
production was greater using overnight induction in both constructs.  
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Figure 4.6 Overproduction of VirG53 and VirG103 in pET32a with E. coli BL21 (DE3) 
cells in different induction times. (BF: Pre-induction, 3hrs: 3 hours, O/N: overnight). 
 
Overnight induction protein samples were analysed further. Pellets were sonicated and 
centrifuged to separate the supernatants and pellets. Both samples were prepared and loaded 
to 12% SDS-PAGE gel. Most of VirG103 was found in the insoluble fraction while some of 
the VirG53 were found in the soluble fraction (Figure. 4.7).  
 
Figure 4.7 Overproduction of VirG53 and VirG103 in pET32a with BL21 (DE3) in 
overnight induction. (AF: Post-induction, SUP: Supernatant, PPT: Pellet).  
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4.2 Overproduction of the alpha domain of VirG using pET20b 
The pET-20b(+) vector carries an N-terminal pelB signal sequence for potential periplasmic 
localization and adds 6x Histidine sequence at the C-terminal of protein during expression 
process.   The DNA fragments that encod VirG 53 and VirG103 alpha domain of VirG were 
successfully cloned into pET20b. Figure 4.8 shows digestion of pET20bVirG53 and 
pET20bVirG103 constructs. Insert were identified using agarose gel electrophoresis.  
 
Figure 4.8 Confirmation that alpha-domain VirG103 and VirG53 were successfully 
ligated into pET20b vector by agarose gel electrophoresis. 
 
pET20bVirG53 was transformed into Rosetta-gami™2 (DE3) pLysS competent cell. A single 
colony was inoculated into Luria–Bertani (LB) media containing Cam (12.5 μg /ml), Tet (30 
μg /ml), Amp (100 μg /ml) overnight at 37oC.  
10ml of overnight culture was added to 1L of LB media and the cell culture was grown at 
37oC for 5 hours until the optical density was approximately ~0.6. 1L of cell culture was 
induced the protein with final concentration of 1mM IPTG for overnight at 30 oC.  
The extent of over-expression of VirG was determined by 12% SDS-PAGE gel in post-
induction cell culture sample. Induced cell were resuspened by 20mM Tris-HCl pH8.0, 
500mM NaCl, 10mM Imidazole.  Cell culture were sonicated and centrifuged. Supernatant 
was loaded to HiTrap column (GE Healthcare) for protein purification.  
Protein purification by HiTrap column were showed in Chaptor 2. The elution buffer in this 
study was 20mM TrisHCl pH8.0, 500mM Immidazole, 500mM NaCl. 5ml of elution fraction 
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were collected per tube. A high concentration of protein in fractions A9 and A10 was 
indicated by SDS PAGE gel (Figure 4.9). These two fractions contained contaminant 
therefore, these fractions were pooled and concentrated from 10ml to 1.0ml by MWCO 
10,000 vivaspin (Generon) concentrator for further purification by size exclusion column. 
 
Figure 4.9 Protein has been expressed by pET20bVirG53 with Rosetta2 (DE3) pLysS 
competent cells. The protein has been purified with HiTrap chelating column and 
selected fractions (A9, A10 and A11) were concentrated with MWCO 10,000 vivaspin. 
The histidine tag is still attached to the protein.  
 
The concentrated protein sample was then centrifuged at 13,000 rpm for 10 minutes at 4oC to 
remove any aggregated protein prior to running the size exclusion column. Protein sample 
were loaded on to a Superdex 200 10/300 column (GE Healthcare). The column was 
equilibrated using buffer (20mM Tris-HCl pH8.0, 500mM NaCl) before running the column. 
1.0ml of protein sample was collected per tube.  
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Figure 4.10 Comparison of location of the eluted VirG53 protein with Histidine tag that 
was produced in different conditions. Locations of the eluted protein were determined 
by chromatogram (left) and SDS PAGE (right). Protein has been expressed by a) 
pET32aVirG53 with BL21 (DE3) competent cell and by b) pET20bVirG53 with 
Rosetta2 (DE3) pLysS competent cell. The protein has been purified using Superdex 200 
10/300 size exclusion column and results were showen in the chromatogram. Blue arrow 
specifiy the peak and the fructions that contain protein of interest. a) Protein was 
indicated in fraction 1, 2 and 3 of peak 1 which were void fractions. On the other hand, 
b) Protein was indicated in fraction 6, 7 and 8, that were between the fractionation 
ranges, of peak 2. Fraction 6, 7 and 8 from b) condition were selected and were 
concentrated with MWC10, 000 vivaspin (Generon) for further experiment. Histidine 
tag is still attached to the protein (white arrow).  
300 
200 
100 
0 
200 
150 
100 
50 
0 
Peak 1 Peak 2 
Peak 1 Peak 2 
Peak 1 Peak 2 
Peak 3 
Peak 2 Peak 1 Peak 3 
a) 
b) 
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Figure 4.10 shows chromatogram and the protein fraction from the size exclusion column. 
VirG proteins were eluted in the fraction 6, 7 and 8 at the secondpeak. The first and third 
peaks did not contain VirG.  
The Superdex 200 10/300 column separates the protein size between 10,000 and 600, 000 
(the fractionation range). Proteins that were more than 600kDa were too large to be 
fractionated by the column and eluted in the void volume. The void volume of the Superdex 
200 10/300 column was 8ml (1/3 of volume in total bed volume of column 24ml). Fractions 
6-8 were eluted at 18-21ml (fraction: 1.5 ml/tube). This suggested that VirG protein was no 
longer producing high molecular weight protein complex in the solution as has been seen in 
the experiment (Figure 4.10 a).  VirG fraction 6, 7 and 8 were collected and concentrated by 
using a 10,000 MWCO concentrator.  
Protein crystallisation screens were setup using VirG35-His (3.2mg/ml) using Morpheus® 
Additive OptiMax Kit (See apendex for the compostion of screen) Molecular dimentions) and 
Crystal screens 1 and 2 (See apendex for the compostion of screen, Hampton Reserch). VirG 
protein was introduced into hanging-drop vapor diffusion crystallization trials in 96 well 
plates at 19ºC. Sample (500nl) and reagents (500nl) were dispensed and mixed in the 96 well 
plates by the automated liquid dispenser, Mosquito (TTP Labtech). 
 
 
Figure 4.11 Hanging drop vapour diffusion crystallization experiment 
 Some of the trials showed precipitation in the protein drop, but no crystals were produced. 
Vacuum grease 
 
  
                                                                   
 
 
 
 
 
 
 
 
Chapter 5 
 
Over-production and purification of 
WIP-WASP 
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5.1 Overexpression and production of N- Wiskott–Aldrich syndrome protein (WASP) 
One method of enhancing the solubility of the alpha domain of VirG may have been to co-
express the alpha domain together with its binding partner N-Wiskott–Aldrich syndrome 
protein (WASP).  Therefore, WASP-interacting protein (WIP)-WASP was overproduced in 
order to check its solubility prior to co-expression with VirG.  The structure of WIP-WASP 
structure has been characterised by NMR (Volkman et al., 2002), but not by X-ray 
crystallography. WIP-WASP was also used in crystallization trials. 
The pBH-WIP-WASP construct was kindly provided by Prof. Wendell Lim from 
University of California. pBH is derived from the pET19b vector and contains a TEV 
protease site and a His-tag.  The solubility of the WH1 domain of N-WASP was greatly 
enhanced by its interaction with WIP and the fusion protein WIP-WASP comprises a 
fragment of WIP (residues 461-485) and the WH1 domain of N-WASP (residues 26-147) 
linked by a Gly-Ser-Gly-Ser-Gly linker. The study showed the N-terminal fusion of WH1 
with the WIP peptide was highly soluble compared to the C-terminal fusion (Volkman et al., 
2002).  
The pBHWIP-WASP plasmid was transformed into E.coli BL21 cells. Over-produced 
WIP-WASP was then purified following the method described by Volkman et al., apart from 
cleavage of the His tag from the fusion protein. The result showed that purified His tagged 
fusion WIP-WASP was produced in high yield and solubility (Fig. 5.1). Hampton research 
crystal trails I and II (Hampton Research) were used for WIP-WASP crystallisation trials. 1μl 
of resovor and 1μl of protein were used for hanging drop method.  Protein crystals were not 
produced.  
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Figure 5.1 High level overexpression of wip-wasp in pBH4 analysed using 12% SDS-
PAGE. M:markers(SeeBlue® Pre-stained Protein Standard) 
. 
 
 
5.2 Construction of a plasmid to over-produce the alpha domain of VirG in complex 
with WASP interaction protein (WIP) and Wiskott-Aldrich syndrome protein (WASP)   
 
Previous experiments showed poor expression of soluble virG-alpha domain and the 
aggregation of purified VirG. The latter might have been due to the formation of 
inappropriate disulfide bonds involving the three cysteine residues in the alpha domain of 
VirG. In order to improve solubility of VirG by promoting disulfide exchange and the correct 
folding of the protein, expression vector pET32a was used for expression of virG as the 
vector encodes thioredoxin that reduces disulfide bonds to enable their rearrangement and 
facilitate folding of the protein. In addition, the Neural Wiskott-Aldrich syndrome protein (N-
WASP) is known to interact with amino acid residues 53-506 of the alpha domain of VirG to 
initiate actin-polymerisation (Suzuki et al., 1998;, 2002). Co-expression of the virG region 
corresponding to the alpha domain and wip-wasp or wasp alone may give a soluble complex. 
Therefore, wip-wasp will be cloned downstream of virG in pET32a to produce a bicistronic 
constructs illustrated in Figure. 5.2. Cloning of VirG53 were shown in Chapter 4. 
 
WIP-WASP 
(17kDa)                                
M 
kDa 
28 
17 
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Figure 5.2 VirG and WIP-WASP in the bicistronic construct 
NcoI 
 
BamHI 
 
virG 
BamHI and NotI  restriction 
enzyme treatment and ligation 
NotI RBS       wip-wasp NcoI virG BamHI 
NotI RBS       wip-wasp BamHI 
SalI 
pET32aVirG
-WIP-WASP 
pET32aVirG 
WIP-WASP PCR products 
NcoI BamHI virG 
NcoI and BamHI restriction 
enzyme treatment and ligation 
pET32aVirG 
VirG alpha domain PCR products 
   Multiple restriction enzyme sites 
pET32aVirG Construct 
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5.2.1 wip-wasp PCR amplification 
wip-wasp were amplified by PCR using following primers.  
WIP-WASP  
Primer 
Forward 
5'-CATGGATCCAAGGAGATATACATGGATTTG -3' 
               BamHI 
primer 
Reverse 
5'- ATGGCGGGCGCTCACTCGAGATCTCGTCTT-3' 
                   NotI 
 
Table 5.1 Primers used for amplification of wip-wasp 
 
The reaction mixture was optimized by different primer concentrations (1µM, 0.5µM 
and 0.1 µM). GoTaq polymerase was used for this amplification. Figure 5.3 (b) shows WIP-
WASP was successfully amplified in all conditions. The condition containing high 
concentration of primer (1µM) had high yield of PCR products. All PCR products were 
purified by gel extraction kit (QIAGEN). Amplified wip-wasp was digested with two 
enzymes, BamHI and NotI. 
 
Initial 
Denature 
95Co 2 min 
Denature 95Co 1 min 
Annealing 59Co 30sec 
Extension 72Co 30 sec 
Number of 
Cycles 
35 
Extra 
extension 
72Co 5 min 
 
 
 
 
 
 
 
Figure 5.3   (a) PCR cycle for WIP-WASP using GoTaq polymerase. (b) WIP-WASP 
PCR products confirmed by gel electrophoresis  
 
M    1M 0.5M 0.1M    M 
Kb.p 
 
 
 
 
1.0 
0.8 
0.6 
(a) (b) 
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pET32aVirG53 was digested with BamHI and NotI and attempted ligation with WIP-WASP 
PCR product that was also digested with same restriction enzyme. However, the ligations 
were not successful. 
 
 5.3 Purification and crystallization of the WIP-WASP fusion protein  
pBH4::WASP is the construct which has WIP-WASP insert in a vector derived from pET19b. 
This plasmid was transferred into BL21plysS (DE3) competent cells and transformants were 
grown on ampicilin LB-agar plates at 37°C.  1mM final concentration of IPTG was used for 
protein induction. 
The pellet was resuspended in binding buffer (50mM phosphate buffer, 300mM NaCl, 10mM 
immidazole, pH8.0). The cells were sonicated and centrifuged at 15,000rpm for 45min at 
4°C. The supernatant was applied to HiTrap Chelating Ni column (GE Healthcare) and 
purified WIP-WASP was eluted by using elution buffer (50mM phosphate buffer, 300mM 
NaCl, 500mM immidazole, pH8.0). Further protein purification was done by size-exclusion 
chromatography (Figure 5.4(b)). WIP-WASP was eluted by elution buffer (50mM phosphate 
buffer, 300mM NaCl). 
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Figure 5.4 Purification of the WIP-WASP fusion protein.  (a) 12% SDS-PAGE of WIP-
WASP fusion protein eluted from Ni-Column. Lanes 1 to 7 on the SDS-PAGE gel 
represents the samples that were taken from each fractions (B6-B1 and C2) at the peak 
conformed on the elution profile of Ni-column. Arrow shows the WIP-WASP fusion 
protein (17kDa). The elution profile is not shown.  (b) Elution profile from HiLoad 
16/600 Superdex 75 pg size-exclusion column (GE healthcare). (c) 12% SDS-PAGE of 
WIP-WASP fusion protein eluted from size-exclusion column. Samples are WIP-WASP 
fusion protein from Ni-column (lane1) and from size exclusion column (lane 2-13). 
Latter samples were taken from each fractions (B6, C2, C6-C12, E5 and F12) at peak 1-
5 shown in Figure.5.4(b). Arrow shows the WIP-WASP fusion protein (17kDa). 
 
 
(a) 
(c) 
M: Maker, 1: Pooled fraction (B6-C2) from Ni-column, 2: Flow through 
3:B6, 4:C2, 5:C6, 6:C7, 7:C8, 8:C9, 9:C10, 10:C11, 11:C12, 12:E5, 13:F12  
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There were five distinctive peaks (Figure 5.4 (b)) after WIP-WASP was purified by size 
exclusions chromatography. Figure 5.4 (c) shows the purified WIP-WASP by size exclusion 
column analyzed by SDS-PAGE. The SDS-PAGE gel shows that the second and third peaks 
gives comprise WIP-WASP. However, the second peak was in the void fraction. This 
suggests that some of the WIP-WASP in the fractions of second peak may have aggregated or 
formed a high molecular mass complex. Also the result of SDS-PAGE conformed that there 
were no WIP-WASP in the fractions of first, fourth and fifth peak. Therefore, fractions of 
third peak were pooled, concentrated and used for crystallization trails using Hampton 
research crystallization screens I and II.  The WIP-WASP fusion can be made in large 
quantities (4mg from 1L cells) as a soluble protein.
  
 
 
 
 
 
 
 
Chapter 6 
 
Conclusion and future work 
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6.1 Concluding comments  
Shigella infection is the cause of a large number of deaths in the developing world.  
Infection by Shigella involves several steps one of which is the movement of Shigella 
between an infected cell and an adjacent uninfected cell. This movement is generated by actin 
polymerisation at one pole of the Shigella bacterium.  It is known that VirG is the protein 
which is anchored on the surface of the Shigella bacterium that reclutes the polymerisation of 
actin.  
The alpha domain of VirG, amino acid residues 53-506, which is auto-transported to 
the surface of the bacterial outer membrane by the beta domain, binds multiple partners 
including: N-WASP (Suzuki et al. 1998; 2002), IcsB and vinculin.  VirG also has an IspP 
cleavage site (Figure 1.7).  The binding of N-WASP is known to recruit the APR2/3 complex 
that causes the polymerisation of actin and the generation of an “actin comet” forcing 
Shigella into the neighbouring cell. In order to understand the molecular basis of the 
dissemination of Shigella infection deeper into tissues, the alpha domain of VirG was studied.  
 
The genes encoded two different domain of VirG alpha (VirG R103-A433 and VirG 
T53-V506) were cloned in to the several different expression vectors for protein production: 
pGEX2T, pET32a, and pET20b in order to improve better yield of soluble protein.  In total of 
five constructs were successfully produced in this study. The mutation of one of the construct 
was succeeded at Cys 130 within the VirGT53-V506 for the purpose of inducing soluble 
protein. GST-or His-tagged VirG proteins were produced from these constructs. However, 
VirG protein from Shigella flexineri has proven to be remarkably difficult to produce in 
soluble form in E. coli in this study.   
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The advantage of the pGEX2T, pET14b, pET20b and pET32a expression plasmids 
are that pGEX2T encodes a glutathione S-transferase (GST) tag and pET vector encodes 
hexahistidine-tag which can be readily purified using a GST and nickel column respectively.  
Also GST tag is a soluble protein therefore it may aid the folding of the protein to which it is 
attached.  The hexahistidine tag is small compared to the GST-tag and so problems of 
solubility would not be masked as effectively, this might allow the induction and growth to 
be investigated unhampered by effects of the GST-tag.  
 
GST-tagged VirG α-domain (T53-V506), produced by the transformation of the 
pGEX2TVirG53 plasmid into E. coli (DE3) cells, was partly in the soluble fraction but 
mostly in the insoluble fraction. The soluble fraction of α-domain eluted in the void volume 
of the size exclusion column whether the protein was with or without GST-tag.  This protein 
was confirmed as pure VirG α-domain by SDS-PAGE. The same fraction was analysed by 
dynamic light scattering the data supported the view that the α-domain.  Taken together these 
results reveal that the α-domain is making a large complex or is aggregated in the solution.   
In an attempt to improve the production of soluble VirG α-domain, the 
pET14bVirG53 construct was used. However, amount of soluble protein produced with this 
construct were similar to the protein that was produced by pGEX2T vector. These results 
showed that both proteins that were attached to GST or His-tag could not improve the 
solubility of VirG53 protein. 
 
From the result above, it is possible that the insoluble protein was due to an incorrect 
pattern of disulphide bridges within three cysteine residues that were found in the VirG α-
domain. Disulfide bonds in proteins are formed between two cysteine residues by oxidation 
of the thiol (SH) groups of cysteine residues under appropriate oxidizing conditions. To 
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explore this possibility one of three cysteine (Cys 130) was mutated to serine. Mutated alpha 
domain VirG C130S was cloned into the pGEX2T vector.  The construct produced more 
soluble protein than did the non-cysteine mutant but the amount of soluble protein was still 
low.  
  
The T53-V506 and R103-A433 regidues of VirG alpha domains were then cloned into 
pET32a and pET20b. 103-433 alpha domains were minimum length of alpha domain that 
contains all known binding site. VirG53-506 was found to be insoluble or aggregated in 
solution according to the previous experiment with pGEX2T and pET14b constructs. 
Therefore a shorter alpha domain was also cloned the expression vectors if produced protein 
can be solubilised better. pET32a encodes thioredoxin which reduces disulphide bonds to 
enable their rearrangement and facilitate folding of the protein. The pET20b construct has the 
advantages of targeting VirG to the periplasm by a PelB signal peptide, not the cytoplasm as 
with the other constructs used, to facilitate disulphide formation and having the affinity-tag at 
the C-terminus where it is known peptide can be accommodated.  
Although the constructs made in pET14b and pGEX2T could produce proteins, the proteins 
were partially insoluble and aggregated in solution. Protein produced with new constructs 
with various competent cells were attempted in order to improve the solubility of protein.  
However the VirG protein seems very insoluble in solution in in vitro experiments. 
The protein produced by four constructs (pET32aVirG53, pET32aVirG103, 
pGEX2TVirGC130S and pET20bVirG103) had similar characteristics to those produced by 
the original constructs.  Proteins that were produced by these four constructs were found in 
inclusion bodies, which werelocated in the insoluble pellet as identified by SDS-PAGE. 
Precipitation in the soluble fraction was also observed which indicates that the protein is 
aggregating in solution. A high concentration of NaCl in the buffer seems increase the 
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solubility of protein as lack of salt in the buffer leads to precipitation of protein. A low 
concentration of protein in the buffer containing 500mM NaCl had no precipitation but high 
concentration of protein in the same buffer still precipitated.  Adding detergent to the buffer 
with concentrated protein did not enhance solubility. The study also investigated expression 
at different temperatures (16 and 30°C), different IPTG concentrations (0.5mM and 1mM) 
and induction times (3 hours and overnight). Low temperature caused less protein to be 
produced. Protein production at the low temperature was more soluble than that produced at 
high temperature presumably because the the protein is being produced less quickly and not 
immediately put into inclusion bodies. However, the protein produced at the lower 
temperature may just have insoluble protein in smaller aggregates. Higher temperature, high 
IPTG concentration and long induction time increases the amount of protein but not the 
quantity of soluble protein.  
The study showed that protein produced by pET20bVirG53 with Rossetta (DE3) 
pLysS construct eluted from the size exclusion column in the fractionating range, not in the 
void fraction. This result supported the view that the VirG53 produced was soluble. The 
pET20bVirG53 construct prodces a protein with a C-terminal tag. In the bacterium VirG is 
transported to the periplasm where it folds and is transfered to the outer membrane via a 
transporter. Recombinant VirG produced by pET20b has signal peptide at C-terminus and 
His tag at the N-terminus. The arrangement of signal peptide and tag at each terminus of the 
VirG protein is a similar arrangement to that of wild type full length VirG protein.  Protein 
folding in periplasm may have improved and led to an increase in solubility. Also Rosetta2 
(DE3) pLysS strains were used as a host of protein production by pET20bVirG53. Rosetta 2 
host strains are BL21 derivatives designed to enhance the expression of eukaryotic proteins 
that contain codons rarely used in E. coli. Four rare codons (ATA, AGA, CTA and CCC) 
were found in VirG53 DNA sequence. Therefore an improvement of solubilisation in this 
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study may have also been accelerated by tRNAs for 7 rare codons (AGA, AGG, AUA, CUA, 
GGA, CCC, and CGG) that supplied by the host in vitro environment.  
 
VirG protein produced from pET20bVirG53 by Rosetta2 (DE3) pLysS was used for 
protein crystallisation. However, crystals were not produced. Soluble N-WASP was 
successfully produced in this study. N-WASP was known to bind to VirG alpha domain in 
nature. The VirG/N-WASP complex might be more soluble and afford a way forward. 
 
4.2 Future work  
It is surprising that the production of soluble Shigella flexneri VirG alpha-domain has  
proved so troublesome in E. coli.  It may be that in Shigella there is a periplasmic or  
cytoplasmic chaperone that facilitates the folding of VirG.   
Chaperones act by preventing inappropriate interactions (i.e. misfolding) and giving the  
protein a chance to fold in a molecular cavity that facilitates correct folding.   
Another possibility is that there is an ancillary binding protein that stabilises the  
folded form of the VirG alpha-domain.  It is possible that the β-domain is essential for the 
folding of the α-domain. 
 
A high throughput cloning strategy where a large number of constructs are generated may  
be a useful way forward, especially when combined with an expression and solubility  
screen.  Addition of green fluorescent protein to the C-termini of the protein and  
observation of fluorescence might indicate the correct folding of the attached VirG  
domain, if the VirG domain folds correctly then the GFP domain might also fold correctly 
and fluoresce. 
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A simpler method would be to try expression in a different system.  E. coli is the  
simplest system for protein production, next in complexity and timescale is yeast.   
Expression in Pitchia pastoris has recently been used in the laboratory to make active  
protein that could not be made in active form in E. coli.  The vector manipulation is  
done in E. coli and then the plasmid is transfected into the yeast.  Expression in yeast is what 
I would like to try next in my search for a method to successfully produce soluble and 
functional VirG alpha domain. 
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DNA and Protein sequence of VirG 103-433 
 
DNA 307-1299 (993bp) 
 
aga act aag cta cgg att aac tct gat att atg att agc gca ggt cat ggt ggt gct 
ggt gat aat aat gat ggt aat agt tgt ggc ggt aat ggt ggt gac tct att acc gga 
tct gac ttg tct ata atc aat caa ggc atg att ctt ggt ggt agc ggc ggt agc ggt 
gct gac cat aac ggt gat ggt ggt gag gct gtt aca gga gac aat ctg ttt ata ata 
aat gga gaa att att tca ggt gga cat ggt ggc gat agt tat agt gat agt gat ggg 
ggg aat gga ggt gat gcc gtc aca gga gtc aat cta ccc ata atc aac aaa ggg act 
att tcc ggt ggt aat gga ggt aac aat tat ggt gag ggt gat ggc ggt aat gga ggt 
gat gcc atc aca gga agc agc ctc tct gta atc aat aag ggc acg ttc gct gga ggc 
aac gga ggt gct gct tac ggt tat ggt tat gat ggc tac ggt ggt aat gct atc aca 
gga gat aac ctg tct gta atc aac aat gga gct att tta ggc ggt aat ggt gga cat 
tgg ggg gat gct ata aat ggt agc aat atg acc att gct aat agc gga tat ata att 
tca ggt aaa gaa gat gat gga aca caa aat gta gca ggt aat gct atc cac atc act 
ggt gga aac aat tca tta ata ctc cat gaa ggt tct gtc att act ggt gat gta cag 
gtt aac aat tca tcc att ctg aaa att atc aac aat gat tac act ggg acc aca cca 
act att gaa ggt gat tta tgt gct ggt gat tgt aca act gtt tca cta tca ggt aac 
aaa ttc act gtt tca ggt gac gtt tct ttt ggt gag aac agt tct tta aat tta gct 
gga atc agt agt ctg gaa gct tct gga aat atg tca ttt ggc aac aat gta aaa gtg 
gag gct att ata aat aac tgg gcg 
 
Protein sequence 103-433 
 
        10         20         30         40         50         60  
RTKLRINSDI MISAGHGGAG DNNDGNSCGG NGGDSITGSD LSIINQGMIL GGSGGSGADH  
 
        70         80         90        100        110        120  
NGDGGEAVTG DNLFIINGEI ISGGHGGDSY SDSDGGNGGD AVTGVNLPII NKGTISGGNG  
 
       130        140        150        160        170        180  
GNNYGEGDGG NGGDAITGSS LSVINKGTFA GGNGGAAYGY GYDGYGGNAI TGDNLSVINN  
 
       190        200        210        220        230        240  
GAILGGNGGH WGDAINGSNM TIANSGYIIS GKEDDGTQNV AGNAIHITGG NNSLILHEGS  
 
       250        260        270        280        290        300  
VITGDVQVNN SSILKIINND YTGTTPTIEG DLCAGDCTTV SLSGNKFTVS GDVSFGENSS  
 
       310        320        330  
LNLAGISSLE ASGNMSFGNN VKVEAIINNW A  
 
Number of amino acids: 330 
 
Molecular weight: 32335.57 
 
Theoretical pI: 4.08  
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The rare codon that identified in VirG103-433. 
Rare codon identified by Rare Codon Calculator (RaCC) by NIH MBI Laboratory for 
Structural Genomics and Proteomics. Underlined alphabets represent the rare codon that 
identified in VirG103-433. 
 
Red = rare Arg codons AGG, AGA, CGA  
Green = rare Leu codon CTA  
Blue = rare Ile codon ATA  
Orange = rare Pro codon CCC  
 
for the following input sequence: 
 
aga act aag CTA cgg att aac tct gat att atg att agc gca ggt cat ggt ggt gct 
ggt gat aat aat gat ggt aat agt tgt ggc ggt aat ggt ggt gac tct att acc gga 
tct gac ttg tct ATA atc aat caa ggc atg att ctt ggt ggt agc ggc ggt agc ggt 
gct gac cat aac ggt gat ggt ggt gag gct gtt aca gga gac aat ctg ttt ATA ATA 
aat gga gaa att att tca ggt gga cat ggt ggc gat agt tat agt gat agt gat ggg 
ggg aat gga ggt gat gcc gtc aca gga gtc aat CTA CCC ATA atc aac aaa ggg act 
att tcc ggt ggt aat gga ggt aac aat tat ggt gag ggt gat ggc ggt aat gga ggt 
gat gcc atc aca gga agc agc ctc tct gta atc aat aag ggc acg ttc gct gga ggc 
aac gga ggt gct gct tac ggt tat ggt tat gat ggc tac ggt ggt aat gct atc aca 
gga gat aac ctg tct gta atc aac aat gga gct att tta ggc ggt aat ggt gga cat 
tgg ggg gat gct ATA aat ggt agc aat atg acc att gct aat agc gga tat ATA att 
tca ggt aaa gaa gat gat gga aca caa aat gta gca ggt aat gct atc cac atc act 
ggt gga aac aat tca tta ATA ctc cat gaa ggt tct gtc att act ggt gat gta cag 
gtt aac aat tca tcc att ctg aaa att atc aac aat gat tac act ggg acc aca cca 
act att gaa ggt gat tta tgt gct ggt gat tgt aca act gtt tca CTA tca ggt aac 
aaa ttc act gtt tca ggt gac gtt tct ttt ggt gag aac agt tct tta aat tta gct 
gga atc agt agt ctg gaa gct tct gga aat atg tca ttt ggc aac aat gta aaa gtg 
gag gct att ATA aat aac tgg gcg  
 
The length is: 993 nucleotides 
 
Rare codon in Rosetta cells : Seven rare codons, AUA, AGG, AGA, CUA, CCC, 
GGA, and CGG 
 
 Rare codon 
VirG -
alpha 
domain 
ATA 
(8)* 
----- AGA 
(1)* 
CTA 
(3)* 
CCC 
(1)* 
----- ----- 
Rosetta AUA 
 
AGG AGA CUA CCC GGA CGG 
*The number of codon in the VirG DNA sequence. 
 
Double rare codon : ATA ATA 
Triple rare codon : CTA CCC ATA 
 
 
xv 
 
 
DNA and Protein sequence of VirG 53-506 
DNA 157-1518(1361bp) 
act cct ctt tcg ggt act caa gaa ctt cat ttt tca gag gac aat tat gaa aaa tta 
tta aca cct gtt gat gga ctt tct ccc ttg gga gct ggt gaa gat gga atg gat gcg 
tgg tat ata act tct tcc aac ccc tct cat gca tct aga act aag cta cgg att aac 
tct gat att atg att agc gca ggt cat ggt ggt gct ggt gat aat aat gat ggt aat 
agt tgt ggc ggt aat ggt ggt gac tct att acc gga tct gac ttg tct ata atc aat 
caa ggc atg att ctt ggt ggt agc ggc ggt agc ggt gct gac cat aac ggt gat ggt 
ggt gag gct gtt aca gga gac aat ctg ttt ata ata aat gga gaa att att tca ggt 
gga cat ggt ggc gat agt tat agt gat agt gat ggg ggg aat gga ggt gat gcc gtc 
aca gga gtc aat cta ccc ata atc aac aaa ggg act att tcc ggt ggt aat gga ggt 
aac aat tat ggt gag ggt gat ggc ggt aat gga ggt gat gcc atc aca gga agc agc 
ctc tct gta atc aat aag ggc acg ttc gct gga ggc aac gga ggt gct gct tac ggt 
tat ggt tat gat ggc tac ggt ggt aat gct atc aca gga gat aac ctg tct gta atc 
aac aat gga gct att tta ggc ggt aat ggt gga cat tgg ggg gat gct ata aat ggt 
agc aat atg acc att gct aat agc gga tat ata att tca ggt aaa gaa gat gat gga 
aca caa aat gta gca ggt aat gct atc cac atc act ggt gga aac aat tca tta ata 
ctc cat gaa ggt tct gtc att act ggt gat gta cag gtt aac aat tca tcc att ctg 
aaa att atc aac aat gat tac act ggg acc aca cca act att gaa ggt gat tta tgt 
gct ggt gat tgt aca act gtt tca cta tca ggt aac aaa ttc act gtt tca ggt gac 
gtt tct ttt ggt gag aac agt tct tta aat tta gct gga atc agt agt ctg gaa gct 
tct gga aat atg tca ttt ggc aac aat gta aaa gtg gag gct att ata aat aac tgg 
gcg cag aag gac tat aaa ctg cta agt gca gat aaa ggg ata aca ggt ttc agt gtt 
tct aat ata tct atc atc aat ccg tta ctc act act ggt gct att gac tat aca aaa 
agc tat atc agt gac cag aat aaa ttg atc tac ggt ttg agc tgg aat gat aca gat 
ggc gac agt cat gga gag ttc aat ctg aaa gaa aac gct gaa ctt act gtt 
 
 
Protein Sequence T53-V506 
 
53TPLSGTQELH FSEDNYEKLL TPVDGLSPLG AGEDGMDAWY ITSSNPSHAS RTKLRINSDI  
 
MISAGHGGAG DNNDGNSCGG NGGDSITGSD LSIINQGMIL GGSGGSGADH NGDGGEAVTG  
 
DNLFIINGEI ISGGHGGDSY SDSDGGNGGD AVTGVNLPII NKGTISGGNG GNNYGEGDGG  
 
NGGDAITGSS LSVINKGTFA GGNGGAAYGY GYDGYGGNAI TGDNLSVINN GAILGGNGGH  
 
WGDAINGSNM TIANSGYIIS GKEDDGTQNV AGNAIHITGG NNSLILHEGS VITGDVQVNN  
 
SSILKIINND YTGTTPTIEG DLCAGDCTTV SLSGNKFTVS GDVSFGENSS LNLAGISSLE  
 
ASGNMSFGNN VKVEAIINNW AQKDYKLLSA DKGITGFSVS NISIINPLLT TGAIDYTKSY  
 
ISDQNKLIYG LSWNDTDGDS HGEFNLKENA ELTV506   
 
Number of amino acids: 454 
 
Molecular weight: 45679.1 
 
Theoretical pI: 4.16 
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The rare codon that identified in VirG53-506. 
Rare codon identified by Rare Codon Calculator (RaCC) by NIH MBI Laboratory for 
Structural Genomics and Proteomics. Underlined alphabets represent the rare codon that 
identified in VirG53-506 (1362 nucleotides). 
Red = rare Arg codons AGG, AGA(1), CGA  
Green = rare Leu codon CTA (4) 
Blue = rare Ile codon ATA  (11) 
Orange = rare Pro codon CCC  (3) 
 
for the following input sequence: 
 
act cct ctt tcg ggt act caa gaa ctt cat ttt tca gag gac aat tat gaa aaa tta 
tta aca cct gtt gat gga ctt tct CCC ttg gga gct ggt gaa gat gga atg gat gcg 
tgg tat ATA act tct tcc aac CCC tct cat gca tct aga act aag CTA cgg att aac 
tct gat att atg att agc gca ggt cat ggt ggt gct ggt gat aat aat gat ggt aat 
agt tgt ggc ggt aat ggt ggt gac tct att acc gga tct gac ttg tct ATA atc aat 
caa ggc atg att ctt ggt ggt agc ggc ggt agc ggt gct gac cat aac ggt gat ggt 
ggt gag gct gtt aca gga gac aat ctg ttt ATA ATA aat gga gaa att att tca ggt 
gga cat ggt ggc gat agt tat agt gat agt gat ggg ggg aat gga ggt gat gcc gtc 
aca gga gtc aat CTA CCC ATA atc aac aaa ggg act att tcc ggt ggt aat gga ggt 
aac aat tat ggt gag ggt gat ggc ggt aat gga ggt gat gcc atc aca gga agc agc 
ctc tct gta atc aat aag ggc acg ttc gct gga ggc aac gga ggt gct gct tac ggt 
tat ggt tat gat ggc tac ggt ggt aat gct atc aca gga gat aac ctg tct gta atc 
aac aat gga gct att tta ggc ggt aat ggt gga cat tgg ggg gat gct ATA aat ggt 
agc aat atg acc att gct aat agc gga tat ATA att tca ggt aaa gaa gat gat gga 
aca caa aat gta gca ggt aat gct atc cac atc act ggt gga aac aat tca tta ATA 
ctc cat gaa ggt tct gtc att act ggt gat gta cag gtt aac aat tca tcc att ctg 
aaa att atc aac aat gat tac act ggg acc aca cca act att gaa ggt gat tta tgt 
gct ggt gat tgt aca act gtt tca CTA tca ggt aac aaa ttc act gtt tca ggt gac 
gtt tct ttt ggt gag aac agt tct tta aat tta gct gga atc agt agt ctg gaa gct 
tct gga aat atg tca ttt ggc aac aat gta aaa gtg gag gct att ATA aat aac tgg 
gcg cag aag gac tat aaa ctg CTA agt gca gat aaa ggg ATA aca ggt ttc agt gtt 
tct aat ATA tct atc atc aat ccg tta ctc act act ggt gct att gac tat aca aaa 
agc tat atc agt gac cag aat aaa ttg atc tac ggt ttg agc tgg aat gat aca gat 
ggc gac agt cat gga gag ttc aat ctg aaa gaa aac gct gaa ctt act gtt  
 
 Rare codon 
VirG -
alpha 
domain 
ATA 
(11)* 
----- AGA 
(1)* 
CTA 
(4)* 
CCC 
(3)* 
----- ----- 
Rosetta AUA 
 
AGG AGA CUA CCC GGA CGG 
Double rare codon : ATA ATA 
Triple rare codon : CTA CCC ATA 
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VirG alpha domain protein sequence Thr53-Val506 (MW=45750, PI=4.16, a.a =455) 
 
Gray = Point mutation point (Cysteine (C) → Serine(S) ) 
 
       
53TPLSGTQELH FSEDNYEKLL TPVDGLSPLG AGEDGMDAWY ITSSNPSHAS 
RTKLRINSDI MISAGHGGAG DNNDGNSCGG NGGDSITGSD LSIINQGMIL 
GGSGGSGADH NGDGGEAVTG DNLFIINGEI ISGGHGGDSY SDSDGGNGGD 
AVTGVNLPII NKGTISGGNG GNNYGEGDGG NGGDAITGSS LSVINKGTFA 
GGNGGAAYGY GYDGYGGNAI TGDNLSVINN GAILGGNGGH WGDAINGSNM 
TIANSGYIIS GKEDDGTQNV AGNAIHITGG NNSLILHEGS VITGDVQVNN  
SSILKIINND YTGTTPTIEG DLCAGDCTTV SLSGNKFTVS GDVSFGENSS 
LNLAGISSLE ASGNMSFGNN VKVEAIINNW AQKDYKLLSA DKGITGFSVS 
NISIINPLLT TGAIDYTKSY ISDQNKLIYG LSWNDTDGDS HGEFNLKENA 
ELTVSTILAD NLSHHNINSW DGKSLTKSGE GTLILAEKNT YSGFTNINAG 
ILKMGTV506 
                            
 
VirG alpha domain DNA Sequence(1365bp)  
 
Gray = Point mutation point TGT (TGT=Cysteine-> AGT=Serine) 
 
act cct ctt tcg ggt act caa gaa ctt cat ttt tca gag gac aat tat gaa aaa tta 
tta aca cct gtt gat gga ctt tct ccc ttg gga gct ggt gaa gat gga atg gat gcg 
tgg tat ata act tct tcc aac ccc tct cat gca tct aga act aag cta cgg att aac 
tct gat att atg att agc gca ggt cat ggt ggt gct ggt gat aat aat gat ggt aat 
agt tgt ggc ggt aat ggt ggt gac tct att acc gga tct gac ttg tct ata atc aat 
caa ggc atg att ctt ggt ggt agc ggc ggt agc ggt gct gac cat aac ggt gat ggt 
ggt gag gct gtt aca gga gac aat ctg ttt ata ata aat gga gaa att att tca ggt 
gga cat ggt ggc gat agt tat agt gat agt gat ggg ggg aat gga ggt gat gcc gtc 
aca gga gtc aat cta ccc ata atc aac aaa ggg act att tcc ggt ggt aat gga ggt 
aac aat tat ggt gag ggt gat ggc ggt aat gga ggt gat gcc atc aca gga agc agc 
ctc tct gta atc aat aag ggc acg ttc gct gga ggc aac gga ggt gct gct tac ggt 
tat ggt tat gat ggc tac ggt ggt aat gct atc aca gga gat aac ctg tct gta atc 
aac aat gga gct att tta ggc ggt aat ggt gga cat tgg ggg gat gct ata aat ggt 
agc aat atg acc att gct aat agc gga tat ata att tca ggt aaa gaa gat gat gga 
aca caa aat gta gca ggt aat gct atc cac atc act ggt gga aac aat tca tta ata 
ctc cat gaa ggt tct gtc att act ggt gat gta cag gtt aac aat tca tcc att ctg 
aaa att atc aac aat gat tac act ggg acc aca cca act att gaa ggt gat tta tgt 
gct ggt gat tgt aca act gtt tca cta tca ggt aac aaa ttc act gtt tca ggt gac 
gtt tct ttt ggt gag aac agt tct tta aat tta gct gga atc agt agt ctg gaa gct 
tct gga aat atg tca ttt ggc aac aat gta aaa gtg gag gct att ata aat aac tgg 
gcg cag aag gac tat aaa ctg cta agt gca gat aaa ggg ata aca ggt ttc agt gtt 
tct aat ata tct atc atc aat ccg tta ctc act act ggt gct att gac tat aca aaa 
agc tat atc agt gac cag aat aaa ttg atc tac ggt ttg agc tgg aat gat aca gat 
ggc gac agt cat gga gag ttc aat ctg aaa gaa aac gct gaa ctt act gtt 
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Sequence and DNA map for pET20b(+) 
 
 
 
 
Sequence and map were extracted from snapgene. http://www.snapgene.com 
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Sequence and DNA map for pET32a 
 
 
 
Sequence and map were extracted from Novagen. 
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Sequence and DNA map for pGEX2T 
 
 
 
 
 
 
Sequence and map were extracted from snapgene. http://www.snapgene.com 
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The schematic overview of pET expression system 
 
 
 
 
The figure was extracted from Novagen. 
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Crystal Screen Formulation (Table was taken from Hampton Reserch) 
Reagent [Salt] [Salt] Salt [Buffer] [Buffer] Buffer pH [Ppt 1] [Ppt 1] Precipitant 1 [Ppt 2] [Ppt 2] Precipitant 2
# units units units units
1 0.02 M Calcium chloride dihydrate 0.1 M Sodium acetate trihydrate 4.6 30 % v/v (+/-)-2-Methyl-2,4-pentanediol
2 0.4 M Potassium sodium tartrate tetrahydrate
3 0.4 M Ammonium phosphate monobasic
4 0.1 M TRIS hydrochloride 8.5 2.0 M Ammonium sulfate  
5 0.2 M Sodium citrate tribasic dihydrate 0.1 M HEPES sodium 7.5 30 % v/v (+/-)-2-Methyl-2,4-pentanediol
6 0.2 M Magnesium chloride hexahydrate 0.1 M TRIS hydrochloride 8.5 30 % w/v Polyethylene glycol 4,000
7 0.1 M Sodium cacodylate trihydrate 6.5 1.4 M Sodium acetate trihydrate
8 0.2 M Sodium citrate tribasic dihydrate 0.1 M Sodium cacodylate trihydrate 6.5 30 % v/v 2-Propanol
9 0.2 M Ammonium acetate 0.1 M Sodium citrate tribasic dihydrate 5.6 30 % w/v Polyethylene glycol 4,000
10 0.2 M Ammonium acetate 0.1 M Sodium acetate trihydrate 4.6 30 % w/v Polyethylene glycol 4,000
11 0.1 M Sodium citrate tribasic dihydrate 5.6 1.0 M Ammonium phosphate monobasic
12 0.2 M Magnesium chloride hexahydrate 0.1 M HEPES sodium 7.5 30 % v/v 2-Propanol
13 0.2 M Sodium citrate tribasic dihydrate 0.1 M TRIS hydrochloride 8.5 30 % v/v Polyethylene glycol 400
14 0.2 M Calcium chloride dihydrate 0.1 M HEPES sodium 7.5 28 % v/v Polyethylene glycol 400
15 0.2 M Ammonium sulfate 0.1 M Sodium cacodylate trihydrate 6.5 30 % w/v Polyethylene glycol 8,000
16 0.1 M HEPES sodium 7.5 1.5 M Lithium sulfate monohydrate
17 0.2 M Lithium sulfate monohydrate 0.1 M TRIS hydrochloride 8.5 30 % w/v Polyethylene glycol 4,000
18 0.2 M Magnesium acetate tetrahydrate 0.1 M Sodium cacodylate trihydrate 6.5 20 % w/v Polyethylene glycol 8,000
19 0.2 M Ammonium acetate 0.1 M TRIS hydrochloride 8.5 30 % v/v 2-Propanol
20 0.2 M Ammonium sulfate 0.1 M Sodium acetate trihydrate 4.6 25 % w/v Polyethylene glycol 4,000
21 0.2 M Magnesium acetate tetrahydrate 0.1 M Sodium cacodylate trihydrate 6.5 30 % v/v (+/-)-2-Methyl-2,4-pentanediol
22 0.2 M Sodium acetate trihydrate 0.1 M TRIS hydrochloride 8.5 30 % w/v Polyethylene glycol 4,000
23 0.2 M Magnesium chloride hexahydrate 0.1 M HEPES sodium 7.5 30 % v/v Polyethylene glycol 400
24 0.2 M Calcium chloride dihydrate 0.1 M Sodium acetate trihydrate 4.6 20 % v/v 2-Propanol
25 0.1 M Imidazole 6.5 1.0 M Sodium acetate trihydrate
26 0.2 M Ammonium acetate 0.1 M Sodium citrate tribasic dihydrate 5.6 30 % v/v (+/-)-2-Methyl-2,4-pentanediol
27 0.2 M Sodium citrate tribasic dihydrate 0.1 M HEPES sodium 7.5 20 % v/v 2-Propanol
28 0.2 M Sodium acetate trihydrate 0.1 M Sodium cacodylate trihydrate 6.5 30 % w/v Polyethylene glycol 8,000
29 0.1 M HEPES sodium 7.5 0.8 M Potassium sodium tartrate tetrahydrate
30 0.2 M Ammonium sulfate 30 % w/v Polyethylene glycol 8,000
31 0.2 M Ammonium sulfate 30 % w/v Polyethylene glycol 4,000
32 2.0 M Ammonium sulfate
33 4.0 M Sodium formate
34 0.1 M Sodium acetate trihydrate 4.6 2.0 M Sodium formate
35 0.1 M HEPES sodium 7.5 0.8 M Sodium phosphate monobasic monohydrate 0.8 M Potassium phosphate monobasic
36 0.1 M TRIS hydrochloride 8.5 8 % w/v Polyethylene glycol 8,000
37 0.1 M Sodium acetate trihydrate 4.6 8 % w/v Polyethylene glycol 4,000
38 0.1 M HEPES sodium 7.5 1.4 M Sodium citrate tribasic dihydrate
39 0.1 M HEPES sodium 7.5 2 % v/v Polyethylene glycol 400 2.0 M Ammonium sulfate
40 0.1 M Sodium citrate tribasic dihydrate 5.6 20 % v/v 2-Propanol 20 % w/v Polyethylene glycol 4,000
41 0.1 M HEPES sodium 7.5 10 % v/v 2-Propanol 20 % w/v Polyethylene glycol 4,000
42 0.05 M Potassium phosphate monobasic 20 % w/v Polyethylene glycol 8,000
43 30 % w/v Polyethylene glycol 1,500
44 0.2 M Magnesium formate dihydrate
45 0.2 M Zinc acetate dihydrate 0.1 M Sodium cacodylate trihydrate 6.5 18 % w/v Polyethylene glycol 8,000
46 0.2 M Calcium acetate hydrate 0.1 M Sodium cacodylate trihydrate 6.5 18 % w/v Polyethylene glycol 8,000
47 0.1 M Sodium acetate trihydrate 4.6 2.0 M Ammonium sulfate
48 0.1 M TRIS hydrochloride 8.5 2.0 M Ammonium phosphate monobasic
49 1.0 M Lithium sulfate monohydrate 2 % w/v Polyethylene glycol 8,000
50 0.5 M Lithium sulfate monohydrate 15 % w/v Polyethylene glycol 8,000  
xiv 
 
Crystal Screen 2 Formulation (Table was taken from Hampton Reserch) 
Reagent [Salt 1] [Salt 1] Salt 1 [Salt 2] [Salt 2] Salt 2 [Buffer] [Buffer] Buffer pH [Ppt 1] [Ppt 1] Precipitant 1 [Ppt 2] [Ppt 2] Precipitant 2
# units units units units units
1 2.0 M Sodium chloride 10 % w/v Polyethylene glycol 6,000
2 0.5 M Sodium chloride 0.01 M Magnesium chloride hexahydrate 0.01 M Hexadecyltrimethylammonium bromide
3 25 % v/v Ethylene glycol
4 35 % v/v 1,4-Dioxane
5 2.0 M Ammonium sulfate 5 % v/v 2-Propanol
6 1.0 M Imidazole pH 7.0
7 10 % w/v Polyethylene glycol 1,000 10 % w/v Polyethylene glycol 8,000
8 1.5 M Sodium chloride 10 % v/v Ethanol
9 0.1 M Sodium acetate trihydrate 4.6 2.0 M Sodium chloride
10 0.2 M Sodium chloride 0.1 M Sodium acetate trihydrate 4.6 30 % v/v (+/-)-2-Methyl-2,4-pentanediol
11 0.01 M Cobalt(II) chloride hexahydrate 0.1 M Sodium acetate trihydrate 4.6 1.0 M 1,6-Hexanediol
12 0.1 M Cadmium chloride hydrate 0.1 M Sodium acetate trihydrate 4.6 30 % v/v Polyethylene glycol 400
13 0.2 M Ammonium sulfate 0.1 M Sodium acetate trihydrate 4.6 30 % w/v Polyethylene glycol monomethyl ether 2,000
14 0.2 M Potassium sodium tartrate tetrahydrate 0.1 M Sodium citrate tribasic dihydrate 5.6 2.0 M Ammonium sulfate 
15 0.5 M Ammonium sulfate 0.1 M Sodium citrate tribasic dihydrate 5.6 1.0 M Lithium sulfate monohydrate
16 0.5 M Sodium chloride 0.1 M Sodium citrate tribasic dihydrate 5.6 2 % v/v Ethylene imine polymer
17 0.1 M Sodium citrate tribasic dihydrate 5.6 35 % v/v tert-Butanol
18 0.01 M Iron(III) chloride hexahydrate 0.1 M Sodium citrate tribasic dihydrate 5.6 10 % v/v Jeffamine M-600
19 0.1 M Sodium citrate tribasic dihydrate 5.6 2.5 M 1,6-Hexanediol
20 0.1 M MES monohydrate 6.5 1.6 M Magnesium sulfate heptahydrate
21 0.1 M Sodium phosphate monobasic monohydrate 0.1 M Potassium phosphate monobasic 0.1 M MES monohydrate 6.5 2.0 M Sodium chloride
22 0.1 M MES monohydrate 6.5 12 % w/v Polyethylene glycol 20,000
23 1.6 M Ammonium sulfate 0.1 M MES monohydrate 6.5 10 % v/v 1,4-Dioxane
24 0.05 M Cesium chloride 0.1 M MES monohydrate 6.5 30 % v/v Jeffamine M-600
25 0.01 M Cobalt(II) chloride hexahydrate 0.1 M MES monohydrate 6.5 1.8 M Ammonium sulfate 
26 0.2 M Ammonium sulfate 0.1 M MES monohydrate 6.5 30 % w/v Polyethylene glycol monomethyl ether 5,000
27 0.01 M Zinc sulfate heptahydrate 0.1 M MES monohydrate 6.5 25 % v/v Polyethylene glycol monomethyl ether 550
28 1.6 M Sodium citrate tribasic dihydrate pH 6.5
29 0.5 M Ammonium sulfate 0.1 M HEPES 7.5 30 % v/v (+/-)-2-Methyl-2,4-pentanediol
30 0.1 M HEPES 7.5 10 % w/v Polyethylene glycol 6,000 5 % v/v (+/-)-2-Methyl-2,4-pentanediol
31 0.1 M HEPES 7.5 20 % v/v Jeffamine M-600
32 0.1 M Sodium chloride 0.1 M HEPES 7.5 1.6 M Ammonium sulfate 
33 0.1 M HEPES 7.5 2.0 M Ammonium formate
34 0.05 M Cadmium sulfate hydrate 0.1 M HEPES 7.5 1.0 M Sodium acetate trihydrate
35 0.1 M HEPES 7.5 70 % v/v (+/-)-2-Methyl-2,4-pentanediol
36 0.1 M HEPES 7.5 4.3 M Sodium chloride
37 0.1 M HEPES 7.5 10 % w/v Polyethylene glycol 8,000 8 % v/v Ethylene glycol
38 0.1 M HEPES 7.5 20 % w/v Polyethylene glycol 10,000
39 0.2 M Magnesium chloride hexahydrate 0.1 M Tris 8.5 3.4 M 1,6-Hexanediol
40 0.1 M Tris 8.5 25 % v/v tert-Butanol
41 0.01 M Nickel(II) chloride hexahydrate 0.1 M Tris 8.5 1.0 M Lithium sulfate monohydrate
42 1.5 M Ammonium sulfate 0.1 M Tris 8.5 12 % v/v Glycerol
43 0.2 M Ammonium phosphate monobasic 0.1 M Tris 8.5 50 % v/v (+/-)-2-Methyl-2,4-pentanediol
44 0.1 M Tris 8.5 20 % v/v Ethanol
45 0.01 M Nickel(II) chloride hexahydrate 0.1 M Tris 8.5 20 % w/v Polyethylene glycol monomethyl ether 2,000
46 0.1 M Sodium chloride 0.1 M BICINE 9.0 20 % v/v Polyethylene glycol monomethyl ether 550
47 0.1 M BICINE 9.0 2.0 M Magnesium chloride hexahydrate
48 0.1 M BICINE 9.0 2 % v/v 1,4-Dioxane 10 % w/v Polyethylene glycol 20,000  
 
xiii 
 
MorpheusTM  Additive OptiMax Kit Formulation (Molecular dimenstions) 
Tube Additive/precipitant 
1 1 M Calcium chloride 
2 1 M Magnesium chloride 
3 1 M Sodium bromid 
4 1 M Sodium fluorid 
5 1 M Sodium iodid 
6 1 M Ammonium sulfat 
7 0.5 M Sodium hydrogen phosphate dibasic 
8 1 M Sodium nitrate 
9 100% v/v 1-butanol 
10 100% v/v 1,4-butanediol 
11 70% v/v 1,6-hexanediol 
12 100% v/v 1,2-propanediol 
13 50% v/v 1,3-propanediol 
14 100% v/v 2-propanol 
15 50% v/v Di-ethyleneglycol 
16 0.4 M Penta-ethyleneglycol 
17 40% v/v Tetra- ethyleneglycol 
18 100% v/v  TEG (Tri- ethyleneglycol) 
19 1 M N-Acetyl - D-Glucosamine 
20 1 M L-Fucose 
21 1 M D-Galactose 
22 1 M D-Glucose 
23 1 M D-Mannose 
24 1 M D-Xylose 
25 1 M Ammonium acetate 
26 1 M Potassium sodium tartrate 
27 1 M Sodium citrate 
28 1 M Sodium formate 
29 0.5 M Sodium Oxamate 
30 1 M DL-Alanine 
31 0.2 M DL- Glutamic acid 
32 1 M Glycine 
33 1 M DL- Lysine HC 
34 0.2 M DL- Serine 
35 50% v/v PEG 550 MME 
36 50% v/v PEG 20,000 
37 100% v/v Ethylene glycol 
38 50% v/v PEG 8000 
39 100% v/v Glycerol 
40 50% v/v PEG 4000 
41 100% v/v MPD 
42 50% v/v PEG 1000 
43 50% v/v PEG 3350 
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